Compounds

ABSTRACT

Compounds of formula (I); 
                         
wherein
         R 1  and R 2  are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and   X represents a carboxylic acid group, a carboxylate group, or a carboxamide group;
 
or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed.
       
     A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed. The use of such compounds as medicaments, in particular for the treatment of diabetes type 2, is also disclosed.

PRIORITY CLAIM

This application claims priority under 35 U.S.C. § 119 to provisionalapplication Ser. Nos. 60/677,350, filed May 4, 2005 and 60/677,351,filed May 4, 2005, and also claims priority under 35 U.S.C. § 119 toSwedish Application No. 0501045-9, filed May 4, 2005, and SwedishApplication No. 0501044-2, filed May 4, 2005, the entire contents ofeach of which is incorporated herein, by reference, in its entirety.

TECHNICAL FIELD

The present invention relates to compounds of the general formula (I):

and their use as medicaments, in particular for the treatment ofdiabetes mellitus, type 2, and pre-stages thereof. It also relates to apharmaceutical composition comprising compounds of formula (I), as wellas to a fatty acid composition comprising compounds of formula (I).

BACKGROUND OF THE INVENTION

The increasing incidence of type 2 diabetes mellitus worldwide poses animmense public health and medical challenge for the implementation ofsuccessful preventive and treatment strategies. The concurrent rise inoverweight and obesity, which is tightly correlated to type 2 diabetes,interferes with diabetes treatment and increases the likelihood ofhypertension, dyslipidemia, and atherosclerosis related diseases.

The pathophysiologic condition preluding the development of type 2diabetes is related to reduced effects of insulin on peripheral tissues,called insulin resistance. These tissues are mainly muscle, fat andliver. Muscle tissue is the main tissue concerned by insulin resistancein type 2 diabetes. The syndrome characterised by insulin resistance,hypertension, dyslipidemia and a systemic proinflammatory state, isreferred to as metabolic syndrome. The prevalence of metabolic syndromein the adult population in developed countries is 22-39% (Meighs 2003)

Currently the most promising approach to mitigate and deter themetabolic syndrome is lifestyle intervention with weight reduction,decreased consumption of saturated fat, increased physical activity incombination with appropriate pharmacotherapy. Healthy diets that avoidexcess energy intake encompass substitution of mono and polyunsaturatedfatty acids in exchange for saturated fat. In particular the long-chainomega-3 fatty acids from fatty fish, namely eicosapentaenoic acid (EPA)and docosahexaenoic acid (DHA) have proven beneficial in prevention oftype 2 diabetes.

EPA and DHA have effects on diverse physiological processes impactingnormal health and chronic disease, such as the regulation of plasmalipid levels, cardiovascular and immune function, insulin action andneural development and visual function. Firm evidence exist for theirbeneficial role in the prevention and management of coronary heartdisease, dyslipidemias, type 2 diabetes, insulin resistance, andhypertension (Simonopoulos 1999; Geleijnse 2002; Storlien 1998).

Recent studies suggest that omega-3 fatty acids serve as importantmediators of gene expression, working via nuclear receptors like theperoxisome proliferator-activated receptors (PPARs) controlling theexpression of the genes involved in the lipid and glucose metabolism andadipogenesis (Jump 2002). PPARs are nuclear fatty acid receptors thathave been implicated to play an important role in obesity-relatedmetabolic diseases such as hyperlipidemia, insulin resistance, andcoronary heart disease.

The three subtypes, α, γ, and δ, have distinct expression pattern andevolved to sense components of different lipoproteins and regulate lipidhomeostasis based on the need of a specific tissue. PPARα potentiatesfatty acid catabolism in the liver and is the molecular target of thelipid-lowering fibrates. PPARγ on the other hand is essential foradipocyte differentiation and mediates the activity of theinsulin-sensitizing thiazolidinedions (the glitazones) throughmechanisms not fully understood. (Chih-Hao 2003; Yki-Järvinen 2004)

Recently, pharmaceuticals acting as ligands to the PPARγ receptor havebeen introduced as treatment of type 2 diabetes (Yki-Järvinen 2004).These compounds called thiazolidinediones or glitazones are drugs thatreverse insulin resistance which is the pathophysiologic basis fordevelopment of the metabolic syndrome and type 2 diabetes. Thesecompounds, of which rosiglitazone and pioglitazone have been launched aspharmaceuticals, lower fasting and postprandial glucose concentrations(which is being manifest as a pathologic glucose tolerance test), plasmainsulin as well as free fatty acid concentrations. In this respect theglitazones act as insulin sensitizers.

However, these improvements are generally accompanied by weight gain andan increase in the subcutaneous adipose-tissue mass (Adams 1997). Theuse of thiazolidinediones is not only associated with weight gain but asubgroup of patients also have fluid retention and plasma volumeexpansion, leading to peripheral oedema. The increase in body weight andoedema has been associated with an increase in the incidence of heartfailure, which is the reason why the Food and Drug Administration hasincluded a warning in the prescription information for rosiglitazone(provided by Avandia) and pioglitazone (provided by Takeda). Theseadverse effects restrict the use of the glitazones especially inpatients with coronary heart conditions. Clearly there is a potentialfor new drugs with positive effects on insulin resistance but withweight reduction activity and no fluid retention tendency.

The effect of the poly-unsaturated fatty acids (PUFAs) on PPARs are notonly a result of fatty acid structure and affinity to the receptor.Factors contributing to the composition of the intracellularnon-esterified fatty acids (NEFA) levels are also important. This NEFApool is affected by the concentration of exogenous fatty acids enteringthe cell and the amount of endogenous synthesised fatty acids, theirremoval via incorporation into lipids as well as their oxidationpathways. (Pawar 2003)

Although omega-3 fatty acids are weak agonists of PPARs, when comparedwith pharmacological agonists like the thioglitazones, these fatty acidshave demonstrated improvement in glucose uptake and insulin sensitivity(Storlien 1987). It has been reported that adipocytes were more insulinsensitive and transported more glucose when the polyunsaturated tosaturated fatty acid ratio in the diet was increased (Field 1990).Collectively, these data indicate that the 20- and 22-carbon fattyacids, namely EPA and DHA could play a preventive role in thedevelopment of insulin resistance.

Due to their limited stability in vivo and their lack of biologicalspecificity, PUFAs have not achieved widespread use as therapeuticagents. Chemical modifications of the n-3 polyunsaturated fatty acidshave been performed by several research groups in order to change orincrease their metabolic effects.

For example, the hypolipidemic effects of EPA was potentiated byintroducing methyl or ethyl in α- or β-position of EPA. (Vaagenes 1999).The compounds also reduced plasma free fatty acid while EPA EE had noeffect.

In a recent work published by L. Larsen (Larsen 2005) the authors showthat the α-methyl derivatives of EPA and DHA increased the activation ofthe nuclear receptor PPARα and thereby the expression of L-FABP comparedto EPA/DHA. EPA with an ethyl group in the α-position activated PPARαwith equal strength as α-methyl EPA. The authors suggest that delayedcatabolism of these α-methyl FA may contribute to their increasedeffects due to decreased β-oxidation in mitochondria leading toperoxisomal oxidation.

Alpha-methyl EPA has been shown to be a stronger inhibitor of plateletaggregation than EPA, both in vitro (Larsen 1998) and in vivo (Willumsen1998).

Patent Abstract of Japan, publication number 05-00974 discloses DHAsubstituted in alpha-position with an OH-group, however only as anintermediate. No examination as to possible pharmaceutical effects ofthis compound is disclosed.

Laxdale Limited has also described the use of alpha substitutedderivatives of EPA in the treatment of psychiatric or central nervousdisorders (U.S. Pat. No. 6,689,812).

None of these modified fatty acids have, however, shown satisfactorypharmaceutical activity, and none of them has reached the pharmaceuticalmarket.

SUMMARY OF THE INVENTION

The aim of the present invention is to provide new DHA-derivativeshaving therapeutical activity.

Based on the present invention a number of aspects are presented in theappended claims. Some of these aspects are:

1. Novel compounds, i.e. certain α-substituted polyunsaturated fattyacid derivatives.

2. The novel compounds for use as a medicament and for use in therapy.

3. A fatty acid composition or a pharmaceutical composition comprisingthe novel compounds.

4. A fatty acid composition comprising the novel compounds for use as amedicament and for use in therapy.

5. Use of the novel compounds for the production of a medicament for theprevention and/or treatment of diabetes in humans or an animal.

6. Use of the novel compounds for the production of a medicament for thetreatment and/or the prevention of obesity or an overweight condition.

7. Use of the novel compounds for the production of a medicament forcontrolling body weight reduction and/or for preventing body weightgain.

8. Use of the novel compounds for the production of a medicament for thetreatment and/or prevention of amyloidos-related diseases.

9. Use of the novel compounds for the production of a medicament for thetreatment or prophylaxis of multiple risk factors or cardiovasculardiseases.

10. Use of the novel compounds for the production of a medicament forthe prevention of stroke, cerebral or transient ischaemic attacksrelated to atherosclerosis of several arteries.

11. A method for specific treatment of a diabetic condition, preferablytype 2 diabetes.

12. A method for controlling body weight reduction, for preventing bodyweight gain and/or for the treatment and/or the prevention of obesity oran overweight condition.

13. A method for the treatment and/or prevention of amyloidos-relateddiseases.

14. A method for the treatment or prophylaxis of multiple risk factorsfor cardiovascular diseases.

15. A method for the prevention of stroke, cerebral or transientischaemic attacks related to atherosclerosis of several arteries.

16. Processes for preparing novel fatty acid analogous according to theinvention.

The present invention relates to a compound of formula (I):

wherein

-   -   R₁ and R₂ are the same or different and may be selected from the        group consisting of a hydrogen atom, a hydroxy group, an alkyl        group, a halogen atom, an alkoxy group, an acyloxy group, an        acyl group, an alkenyl group, an alkynyl group, an aryl group,        an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl        group, an alkylsulfonyl group, an amino group, and an alkylamino        group; and    -   X represents a carboxylic acid group, a carboxylate group, or a        carboxamide group,        or any pharmaceutically acceptable salt, solvate, complex or        pro-drug thereof, with the provisos that:    -   the compound of formula (I) is not        (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl        DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl        ester, or alpha-hydroxy DHA ethyl ester.        The provisos correspond to the following cases:    -   when R₁ is a hydrogen atom, then R₂ is not a hydrogen atom;    -   when R₂ is a hydrogen atom, then R₁ is not a hydrogen atom;    -   when R₁ is a methyl group, then R₂ is not a hydrogen atom, and X        is not a carboxylic acid group, a methylcarboxylate, or an        ethylcarboxylate;    -   when R₂ is a methyl group, then R₁ is not a hydrogen atom, and X        is not a carboxylic acid group, a methylcarboxylate, or an        ethylcarboxylate;    -   when R₁ is a hydroxy group, then R₂ is not a hydrogen atom, and        X is not an ethylcarboxylat; and    -   when R₂ is a hydroxy group, then R₁ is not a hydrogen atom, and        X is not an ethylcarboxylat.

In a compound according to the invention, said alkyl group may beselected from the group consisting of methyl, ethyl, n-propyl,isopropyl, n-butyl, sec.-butyl, n-hexyl, and benzyl; said halogen atommay be selected from the group consisting of fluorine, chlorine,bromine, and iodine; said alkoxy group may be selected from the groupconsisting of methoxy, ethoxy, propoxy, isopropoxy, sec.-butoxy,phenoxy, benzyloxy, OCH₂CF₃, and OCH₂CH₂OCH₃; said acyloxy group may beselected from acetoxy, propionoxy, and butyroxy; said alkenyl group maybe selected from the group consisting of allyl, 2-butenyl, and3-hexenyl; said alkynyl group may be selected from the group consistingof propargyl, 2-butynyl, and 3-hexynyl; said aryl group is a phenylgroup; said alkylthio group may be selected from the group consisting ofmethylthio, ethylthio, isopropylthio, and phenylthio; saidalkoxycarbonyl group may be selected from the group consisting ofmethoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, and butoxycarbonyl;said alkylsulfinyl group may be selected from the group consisting ofmethanesulfinyl, ethanesulfinyl, and isopropanesulfinyl; saidalkylsulfonyl group may be selected from the group consisting ofmethanesulfonyl, ethanesulfonyl, and isopropanesulfonyl; said alkylaminogroup may be selected from the group consisting of methylamino,dimethylamino, ethylamino, and diethylamino; said carboxylate group maybe selected from the group consisting of ethyl carboxylate, methylcarboxylate, n-propyl carboxylate, isopropyl carboxylate, n-butylcarboxylate, sec.-butyl carboxylate, and n-hexyl carboxylate; saidcarboxamide group may be selected from the group consisting of primarycarboxamide, N-methyl carboxamide, N,N-dimethyl carboxamide, N-ethylcarboxamide, and N,N-diethyl carboxamide.

In one embodiment of the invention, R₁ and R₂ are selected from thegroup consisting of a hydrogen atom, a hydroxy group, an alkyl group, ahalogen atom, an alkoxy group, an alkylthio group, an alkylsulfinylgroup, an alkylsulfonyl group, an amino group, and an alkylamino group.

In another embodiment of the invention, R₁ and R₂ are selected from thegroup consisting of a hydrogen atom, a hydroxy group, a C₁-C₇ alkylgroup, a halogen atom, a C₁-C₇ alkoxy group, a C₁-C₇ alkyltio group, aC₁-C₇ alkylsulfinyl group, a C₁-C₇ alkylsulfonyl group, an amino group,and a C₁-C₇ alkylamino group. Then, said C₁-C₇ alkyl group may bemethyl, ethyl, or benzyl; said halogen atom may be fluorine or iodine:said C₁-C₇ alkoxy group may be methoxy or ethoxy; said C₁-C₇ alkylthiogroup may be methylthio, ethylthio or phenylthio; said C₁-C₇alkylsulfinyl group may be ethanesulfinyl; said C₁-C₇ alkylsulfonylgroup may be ethanesulfonyl; said C₁-C₇ alkylamino group may beethylamino or diethylamino; and X may represent an ethylcarboxylate or acarboxamide group.

In another embodiment of the invention, R₁ and R₂ are selected from thegroup consisting of a hydrogen atom, a C₂-C₇ alkyl group, a halogenatom, a C₁-C₇ alkoxy group, a C₁-C₇ alkyltio group, a C₁-C₇alkylsulfinyl group, a C₁-C₇ alkylsulfonyl group, an amino group, and aC₁-C₇ alkylamino group; and X represents a carboxylate. Then, said C₂-C₇alkyl group may be ethyl, or benzyl; said halogen atom may be fluorineor iodine: said C₁-C₇ alkoxy group may be methoxy or ethoxy; said C₁-C₇alkylthio group may be methylthio, ethylthio or phenylthio; said C₁-C₇alkylsulfinyl group may be ethanesulfinyl; said C₁-C₇ alkylsulfonylgroup may be ethanesulfonyl; said C₁-C₇ alkylamino group may beethylamino or diethylamino; and X represents a an ethylcarooxylate.

In the compound according to formula (I) of the present invention, R₁and R₂ may be the same or different. When they are different, thecompounds of formula (I) are capable of existing in stereoisomericforms. It will be understood that the invention encompasses all opticalisomers of the compounds of formula (I) and mixtures thereof includingracemates.

Therefore, the present invention includes, where R₁ is different fromR₂, compounds of formula (I) that are racemic or enantiomerically pure,either as the (S) or (R) enantiomer. Therefore, the present inventionincludes, where R₁ is different from R₂, compounds of formula (I) thatare racemic or enantiomeric pure, either as the (S) or (R) stereoisomer.

Within the scope of the invention are enantiomers of the compounds ofthe formula (I), as hereinbefore defined. Moreover, the enantiomers ofthe DHA derivatives according to the invention might be in the form of acarboxylic acid, or a pharmaceutically acceptable salt thereof, anyester, anhydride or amide (primary, secondary, tertiary). The acidderivative might be in the form of a phospholipid or a tri- di- ormonoglyceride.

In one embodiment of a compound of formula (I) according to theinvention, one of R₁ and R₂ represents a C₂-C₇ alkyl group, e.g. ethylor benzyl, and the other one represents a hydrogen atom. Preferably, thealkylgroup is ethyl.

In another embodiment of a compound of formula (I) according to theinvention, one of R₁ and R₂ represents an alkoxy group, e.g. ethoxy ormethoxy, and the other one represents a hydrogen atom.

In another embodiment of a compound of formula (I) according to theinvention, one of R₁ and R₂ represents a halogen atom, e.g. fluorine oriodine, and the other one represents a hydrogen atom.

In another embodiment of a compound of formula (I) according to theinvention, one of R₁ and R₂ represents an alkylthio group, e.g.ethylthio, methylthio or phenylthio, and the other one represents ahydrogen atom. Preferably, the alkylthiogroup is ethylthio.

In another embodiment of a compound of formula (I) according to theinvention, one of R₁ and R₂ represents an alkylsulfonyl group, e.g.ethylsulfonyl, and the other one represents a hydrogen atom.

In another embodiment of a compound of formula (I) according to theinvention, one of R₁ and R₂ represents an amino group, and the other onerepresents a hydrogen atom.

In another embodiment of a compound of formula (I) according to theinvention, one of R₁ and R₂ represents an alkyl-amino group, e.g.ethyl-amino or diethyl-amino, and the other one represents a hydrogenatom.

In a further embodiment of a compound of formula (I) according to theinvention, R₁ and R₂ are the same and represent C₁-C₇-alkyl groups,preferably methyl groups or ethyl groups.

In preferred embodiments of the compound of formula (I), X is acarboxylate, e.g. ethyl carboxylate.

The compound according to the invention may exist in the form of aphospholipid, a tri-, di- or monoglyceride, or in the form of a freeacid.

The alpha-substituted DHA-derivatives according to the invention havevery surprisingly shown excellent results with regard to pharmaceuticalactivity. In particular, the fatty acid derivatives according to thepresent invention possess a huge potential to be used in the treatmentand/or prevention of diabetes and pre-stages thereof.

Another aspect of the present invention relates to a compound of formula(I) for use as a medicament.

The invention also relates to a process for the manufacture of acompound of formula (I). For example, a compound of formula (I) may beprepared from (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA). TheDHA may e.g. originate from a vegetable, a microbial and/or an animalsource, such as a marine fish oil. Another important advantage withcompounds of formula (I) is that the fatty acid analogues can beprepared directly from (all-Z)-4,7,10,13,16,19-docosahexaenoic acid(DHA).

In a preferred embodiment of the invention, the fatty acid analogues offormula (I) are prepared from DHA, wherein said DHA is obtained from atleast one of vegetable, microbial and animal origins, or combinationsthereof. The invention includes therefore derivatives prepared fromDHA-containing oil from microbial origin. Suitable, said DHA is producedfrom a marine oil, such as a fish oil.

Another aspect of the present invention relates to a pharmaceuticalcomposition comprising a compound of formula (I) as an activeingredient. The pharmaceutical composition may further comprise apharmaceutically acceptable carrier. Suitably, a pharmaceuticalcomposition according to the invention is formulated for oraladministration, e.g. in the form of a capsule or a sachet. A suitabledaily dosage of a compound of formula (I) according to the presentinvention is 10 mg to 10 g, in particular 100 mg to 1 g of saidcompound.

In addition, the present invention relates to a fatty acid compositioncomprising a compound of formula (I). At least 60%, or at least 90% byweight of the fatty acid composition may be comprised of said compound.The fatty acid composition may further comprise(all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA),(all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA),(all-Z)-6,9,12,15,18-heneicosapentaenoic acid (HPA), and/or(all-Z)-7,10,13,16,19-docosapentaenoic acid (DPA). The fatty acids maybe present in the form of derivatives. A fatty acid compositionaccording to the present invention may further comprise apharmaceutically acceptable antioxidant, e.g. tocopherol. Within thescope of the present invention is also a fatty acid compositiondescribed above, for use as a medicament.

In a further aspect, the present invention relates to the use of acompound according to formula (I) for the manufacture of a medicamentfor controlling body weight reduction and/or for preventing body weightgain; for the manufacture of a medicament for the treatment and/or theprevention of obesity or an overweight condition; for the manufacture ofa medicament for the prevention and/or treatment of diabetes in ananimal, in particular type 2 diabetes; for the manufacture of amedicament for the treatment and/or prevention of amyloidos-relateddiseases; for the manufacture of a medicament for the treatment orprophylaxis of multiple risk factors for cardiovascular diseases,preferably for the treatment of elevated blood lipids for themanufacture of a medicament for prevention of stroke, cerebral ortransient ischaemic attacks related to atherosclerosis of severalarteries.

In addition, the present invention relates to a method for controllingbody weight reduction and/or for preventing body weight gain; a methodfor the treatment and/or the prevention of obesity or an overweightcondition; a method for the prevention and/or treatment of diabetes, inparticular type 2 diabetes; a method for the treatment and/or preventionof amyloidos-related diseases; a method for the treatment or prophylaxisof multiple risk factors for cardiovascular diseases; a method for theprevention of stroke, cerebral or transient ischaemic attacks related toatherosclerosis of several arteries, wherein a pharmaceuticallyeffective amount of a compound of formula (I) is administered to a humanor an animal. Suitably, the compound of formula (I) is administeredorally to a human or an animal.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic overview of the free fatty acid pool theory.

FIG. 2 shows an overview of the models and methods used in the presentinvention for demonstrating effects on the metabolic syndrome and type 2diabetes

FIG. 3 depicts the free fatty acid concentrations of different compoundsaccording to the invention in liver tissue from animals given thesecompounds in a concentration of 1.5% of total fat content.

FIG. 4 depicts the intracellular concentrations of DHA in liver tissuefrom animals given different compounds according to the invention in aconcentration of 1.5% of total fat content.

FIG. 5 depicts the binding affinities for the PPARγ receptor ofdifferent compounds according to the invention.

FIG. 6 depicts the binding affinities to the nuclear receptor PPARα ofdifferent compounds according to the invention.

FIG. 7 depicts the binding affinities to the nuclear receptor RXRα ofdifferent compounds according to the invention.

FIG. 8 depicts the release of luciferase from transfected cells treatedwith different compounds according to the invention.

FIG. 9 shows the study design of the experiment of block 4.

FIG. 10 shows the change of body weight during 2 weeks of dietintervention after 8 weeks of HF diet.

FIG. 11 shows the results from luciferase activity, i.e. endogenousPPARγ-activity).

FIG. 12 shows the endogenous luciferase activity in differenc compoundsaccording to the invention compared to DHA.

FIG. 13 shows a typical blood glucose elimination curve before and afteranimals with insulin resistance are given a compound with insulinresistance reducing effect.

FIGS. 14, 15 and 16 show different effects of DHA derivatives accordingto the invention on metabolic syndrome and insulin resistance.

DETAILED DESCRIPTION OF THE INVENTION

In the research work leading to the present invention, novelDHA-derivatives were prepared, which showed excellent pharmaceuticalactivity.

Fatty acids enter cells passively or trough G-protein coupledtransporter systems, such as fatty acid transport proteins. Well insidethe cells they are temporarily bound by binding proteins (Fatty acidbinding proteins, FABP), which play an important role in directing fattyacids to various intracellular compartments for metabolism and geneexpression (Pawar & Jump 2003). (FIG. 1 liver cell).

Esterification of fatty acids into triglycerides, polar lipids, andcholesterol esters and their beta-oxidation (mitochondrial andperoxisomal) requires conversion of fatty acids to acyl CoA thioesters.Other pathways, like microsomal NADPH-dependent mono-oxidation andeikosanoids synthesis, utilise non-esterified fatty acids as substrates.All these reactions are likely to influence cellular levels of freefatty acids (non-esterfified) and thereby the amount and type of fattyacids which could be used as ligands to nuclear receptors. Because PPARsare known to bind non-esterified fatty acids it is reasonable to expectthat the composition of the free fatty acid pool is an importantdeterminant in the control of PPAR activity.

The composition of the free fatty acid pool is affected by theconcentration of exogenous fatty acids entering the cells, and theirrate of removal via pathways listed above. Since short and medium chainfatty acids are effectively recruited to these pathways, in practiceonly the long-chain polyunsaturated fatty acids will be available forliganding to nuclear receptors. In addition, fatty acid structure mayalso be an important determinant. Even if a series of mono andpolyunsaturated fatty acids demonstrated affinity to the PPARα receptor,EPA and DHA demonstrated the highest binding capacity in experimentswith rat liver cells (Pawar & Jump 2003).

Searching for fatty acid candidates available for genetic modificationof proteins by interaction with nuclear receptors like the PPARs, it isimportant to verify that the respective fatty acids will be enriched inthe free fatty acid pool.

DHA which enter cells are rapidly converted to fatty acyl-CoA thioestersand incorporated into phospholipids and due to this, the intracellularDHA level is relatively low. These DHA-CoA are also substrate forβ-oxidation primarily in the peroxisomes that lead to retroconvertion ofDHA to EPA, see FIG. 1. Because of the rapid incorporation into neutrallipids and the oxidation pathway DHA will not stay long in the freefatty acid pool. Due to this the effect of DHA on gene expression isprobably limited.

The present invention aims at achieving an accumulation of fatty acidderivatives in the free fatty acid pool, rather than incorporation intophosholipids. The present inventors have surprisingly found that theintroduction of at least one substituent in the α-position of DHA willlead to a slower oxidation rate in addition to less incorporation intoneutral lipids. This will lead to an increased effect on geneexpression, since the DHA derivatives will accumulate in the tissueparticular within liver, muscle, and adipose cells and trigger localnuclear receptor activity to a greater extent than DHA.

The different substituents according to the invention will give variableaffinities of the derivatives to fatty acids binding receptors. It isalso possible that changes in affinity to fatty acids binding proteinslead to changes in the biological activity of these α-substituted DHAderivatives of formula (I). Altogether theses changes lead to anincreased therapeutic effect of the DHA derivatives according to theinvention compared to DHA.

EPA (all-Z)-5,8,11,14,17-eicosapentaenoic acid) has earlier beenalkylated in α- and β-position to inhibit mitochondrial β-oxidation. DHAis not oxidised in the mitochondria, but rather incorporated intophospholipids. In the peroxisomes though some DHA is retroconverted toEPA. A substituent in the α-position of EPA and DHA will due to thisaffect different metabolic pathways. It has earlier been shown thatα-methyl EPA and β-methyl EPA is incorporated into phospholipids andtriglycerids while α-ethyl EPA is not (Larsen 1998). In this study thederivatives were tested as substrates and/or inhibitors of enzymesinvolved in the eicosanoid cascade. Since most of the substrates forthese enzymes are fatty acids liberated from phospholipids it wasdesired that the derivatives were incorporated into phospholipids. Incontrast to this, as mentioned before, we want derivatives that will notincorporate into lipids, but rather accumulate in the NEFA pool.

Througout this description, the abbreviation “PRB-x”, where x is aninteger, will be used when describing specific compounds according tothe invention. Below, the structural formulas and trivial names for eachof these compounds are listed:

PRB-1 α-methyl docosahexaenoic acid ethyl ester

PRB-2 α-ethyl docosahexaenoic acid ethyl ester

PRB-3 α-ethoxy docosahexaenoic acid ethyl ester

PRB-4 α-fluoro dzocosahexaenoic acid ethyl ester

PRB-5 α,α di-methyl docosahexaenoic acid ethyl ester

PRB-6 α-tiomethyl docosahexaenoic acid ethyl ester

PRB-7 α-tioethyl docosahexaenoic acid ethyl ester

PRB-8 α,α di-ethyl docosahexaenoic acid ethyl ester

PRB-9 α-benzyl docosahexaenoic acid ethyl ester

PRB-10 α-ethanesulfinyl docosahexaenoic acid ethyl ester

PRB-11 α-tiophenyl docosahexaenoic acid ethyl ester

PRB-12 α-hydroxy docosahexaenoic acid ethyl ester

PRB-13 α-methyl docosahexaenoic acid

PRB-14 αmethoxy docosahexaenoic acid ethyl ester

PRB-15 α-iodo docosahexaenoic acid ethyl ester

PRB-17 α-amino docosahexanoic acid ethyl ester

PRB-18 (4R,5S)-3-docosahexaenoyl-4-methyl-5-phenyl-oxazolidin-2-one

PRB-19(4R,5S)-3-[(S)-α-ethyldocosahexaenoyl]-4-methyl-5-phenyl-oxazolidin-2-one

PRB-20 (S)-(+)-α-ethyl docosahexanoic acid ethyl ester

PRB-21 (4S,5R)-3-docosahexaenoyl-4-methyl-5-phenyl-oxazolidin-2-one

PRB-22(4S,5R)-3-[(R)-α-ethyldocosahexaenoyl]-4-methyl-5-phenyl-oxazolidin-2-one

PRB-23 (R)-(−)-α-ethyl docosahexanoic acid ethyl ester

PRB-24 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-docos ahexaenoic acidethyl ester

PRB-25 α-ethyl-amino docosahexanoic acid ethyl ester

PRB-26 α-diethyl-amino docosahexanoic acid ethyl ester

PRB-1 corresponds to a compound of formula (I) in which R₁ or R₂ ismethyl, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-2 corresponds to a compound of formula (I) in which R₁ or R₂ isethyl, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-3 corresponds to a compound of formula (I) in which R₁ or R₂ isethoxy, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-4 corresponds to a compound of formula (I) in which R₁ or R₂ isfluorine, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-5 corresponds to a compound of formula (I) in which R₁ and R₂ ismethyl, and X is ethyl carboxylate.

PRB-6 corresponds to a compound of formula (I) in which R₁ or R₂ ismethylthio, and X is ethyl carboxylate.

PRB-7 corresponds to a compound of formula (I) in which R₁ or R₂ isethylthio, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-8 corresponds to a compound of formula (I) in which R₁ and R₂ isethyl, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-9 corresponds to a compound of formula (I) in which R₁ or R₂ isbenzyl, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-10 corresponds to a compound of formula (I) in which R₁ or R₂ isethanesulfinyl, and the other one is hydrogen, and X is ethylcarboxylate.

PRB-11 corresponds to a compound of formula (I) in which R₁ or R₂ isphenylthio, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-12 corresponds to a compound of formula (I) in which R₁ or R₂ ishydroxy, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-13 corresponds to a compound of formula (I) in which R₁ or R₂ ismethyl, and the other one is hydrogen, and X is primary carboxamide.

PRB-14 corresponds to a compound of formula (I) in which R₁ or R₂ ismethoxy, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-15 corresponds to a compound of formula (I) in which R₁ or R₂ isiodine, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-17 corresponds to a compound of formula (I) in which R₁ or R₂ isamino, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-20 corresponds to the (S) stereoisomer of a compound of formula (I)in which R₁ or R₂ is ethyl, and the other one is hydrogen, and X isethyl carboxylate.

PRB-23 corresponds to the (R) stereoisomer of a compound of formula (I)in which R₁ or R₂ is ethyl, and the other one is hydrogen, and X isethyl carboxylate.

PRB-24 corresponds to a compound of formula (I) in which R₁ or R₂ isN-phtalimide, and the other one is hydrogen, and X is ethyl carboxylate.

PRB-25 corresponds to a compound of formula (I) in which R₁ or R₂ isethyl-amino, and the other one is hydrogen, and X is primarycarboxamide.

PRB-26 corresponds to a compound of formula (I) in which R₁ or R₂ isdiethyl-amino, and the other one is hydrogen, and X is ethylcarboxylate.

PRB-2 is the most preferred compound according to the present invention.

Other preferred compounds according to the invention are PRB-5, PRB-7,and PRB-8.

It is to be understood that the present invention encompasses anypossible pharmaceutically acceptable salts, solvates, complexes orprodrogs of the compounds of formula (I).

“Prodrugs” are entities which may or may not possess pharmacologicalactivity as such, but may be administered (such as orally orparenterally) and thereafter subjected to bioactivation (for examplemetabolized) in the body to form the agent of the present inventionwhich is pharmacologically active.

Where X is a carboxylic acid, the present invention also includes saltsof the carboxylic acids. Suitable pharmaceutically acceptable salts ofcarboxy groups includes metal salts, such as for example aluminium,alkali metal salts such as lithium, sodium or potassium, alkaline metalsalts such as calcium or magnesium and ammonium or substituted ammoniumsalts.

A “therapeutically effective amount” refers to the amount of thetherapeutic agent which is effective to achieve its intended purpose.While individual patient needs may vary, determination of optimal rangesfor effective amounts of each nitric oxide adduct is within the skill ofthe art. Generally the dosage regimen for treating a condition with thecompounds and/or compositions of this invention is selected inaccordance with a variety of factors, including the type, age, weight,sex, diet and medical condition of the patient.

By “a medicament” is meant a compound according to formula (I), in anyform suitable to be used for a medical purpose, e.g. in the form of amedicinal product, a pharmaceutical preparation or product, a dietaryproduct, a food stuff or a food supplement.

In the context of the present specification, the term “therapy” alsoincludes “prophylaxis” unless there are specific indications to thecontrary. The terms “therapeutic” and “therapeutically” should beconstructed accordingly.

Treatment includes any therapeutic application that can benefit a humanor non-human animal. The treatment of mammals is particularly preferred.Both human and veterinary treatments are within the scope of the presentinvention. Treatment may be in respect of an existing condition or itmay be prophylactic. It may be of an adult, a juvenile, an infant, afoetus, or a part of any of the aforesaid (e.g. an organ, tissue, cell,or nucleic acid molecule). By “chronic treatment” is meant treatmentthat continues for some weeks or years.

“A therapeutically or a pharmaceutically active amount” relates to anamount that will lead to the desired pharmacological and/or therapeuticeffects.

A compound according to the present invention may for example beincluded in a food stuff, a food supplement, a nutritional supplement,or a dietary product

Alpha-substituted DHA derivatives and EPA (or DHA for that matter) canbe bound together and combined on triglyceride form by an esterificationprocess between a mixture of alpha-derivatives, EPA and glycerolcatalysed by Novozym 435 (a commercially available lipase from Candidaantarctica on immobilised form).

The compounds of formula (I) have activity as pharmaceuticals, inparticular as triggers of nuclear receptor activity. Thus, the presentinvention also relates to compounds of formula (I), pharmaceuticallyacceptable salts, solvates, complexes or pro-drugs thereof, ashereinbefore defined, for use as a medicament and/or for use in therapy.Preferably, the novel compounds, or pharmaceutically acceptable salts,solvates, complexes or pro-drugs thereof, of the invention may be used:

-   -   for the prevention and/or treatment of diabetes mellitus in        humans or animals;    -   for controlling body weight reduction and/or for preventing body        weight gain;    -   for the prevention and/or treatment of obesity or an overweight        condition in humans or in an animal;    -   for the treatment and/or prevention of amyloidos-related        diseases;    -   for the treatment or prophylaxis of multiple risk factors for        cardiovascular diseases;    -   for the prevention of stroke, cerebral or transient ischaemic        attacks related to atherosclerosis of several arteries.    -   for the treatment of TBC or HIV.

There are two major forms of diabetes mellitus. One is type 1 diabetes,which is known as insulin-dependent diabetes mellitus (IDDM), and theother one is type 2 diabetes, which is also known asnon-insulin-dependent diabetes mellitus (NIDDM). Type 2 diabetes isrelated to obesity/overweight and lack of exercise, often of gradualonset, usually in adults, and caused by reduced insulin sensitivity, socalled periferral insulin resistance. This leads to a compensatoryincrease in insulin production. This stage before developing fullfetched type 2 diabetes is called the metabolic syndrome andcharacterized by hyperinsulinemia, insulin resistance, obesity, glucoseintolerance, hypertension, abnormal blood lipids, hypercoagulopathia,dyslipidemia and inflammation, often leading to atherosclerosis of thearteries. Later when insulin production seizes, type 2 diabetes mellitusdevelops.

In a preferred embodiment, the compounds according to formula (I) mayused for the treatment of type 2 diabetes. The compounds according toformula (I) may also be used for the treatment of other types ofdiabetes selected from the group consisting of metabolic syndrome,secondary diabetes, such as pancreatic, extrapancreatic/endocrine ordrug-induced diabetes, or exceptional forms of diabetes, such aslipoatrophic, myatonic or a disease caused by disturbance of the insulinreceptors. The invention also includes treatment of type 2 diabetes.Suitably, compounds of formula (I), as hereinbefore defined, mayactivate nuclear receptors, preferably PPAR (peroxisomeproliferator-activated receptor) α and/or γ.

The compounds of formula (I) may also be used for the treatment and/orprevention of obesity. Obesity is usually linked to an increased insulinresistance and obese people run a high risk of developing type 2diabetes which is a major risk factor for development of cardiovasculardiseases. Obesity is a chronic disease that afflict an increasingproportion of the population in Western societies and is associated, notonly with a social stigma, but also with decreasing life span andnumerous problems, for instance diabetes mellitus, insulin resistanceand hypertension. The present invention thus fulfils a long felt needfor a drug that will reduce total body weight, or the amount of adiposetissue, of preferably obese humans, towards their ideal body weightwithout significant adverse side effects.

The compounds according to formula (I) may also be used for theprevention and/or treatment of amyloidos-related diseases.Amyloidos-related conditions or diseases associated with deposition ofamyloid, preferably as a consequence of fibril or plaque formation,includes Alzheimer's disease or dementia, Parkinson's disease,amyotropic lateral sclerosis, the spongiform encephalopathies, such asCreutzfeld-jacob disease, cystic fibrosis, primary or secondary renalamyloidoses, IgA nephropathy, and amyloid depostion in arteries,myocardium and neutral tissue. These diseases can be sporadic, inheritedor even related to infections such as TBC or HIV, and are oftenmanifested only late in life even if inherited forms may appear muchearlier. Each disease is associated with a particular protein oraggregates of these proteins are thought to be the direct origin of thepathological conditions associated with the disease. The treatment of aamyloidos-related disease can be made either acutely or chronically.

The compounds of formula (I) may also be used for the treatment due toreduction of amyloid aggregates, prevention of misfolding of proteinsthat may lead to formation of so called fibrils or plaque, treatment dueto decreasing of the production of precursor protein such as Aβ-protein(amyloid beta protein), and prevention and/or treatment due toinhibiting or slow down the formation of protein fibrils, aggregates, orplaque. Prevention of fibril accumulation, or formation, byadministering compounds of formula (I), as hereinbefore defined, is alsoincluded herein. In one embodiment, the novel compounds,pharmaceutically acceptable salts, solvates, complexes or pro-drugsthereof, as hereinbefore defined, are used for the treatment of TBC(tuberculosis) or HIV (human immunodeficiency virus).

Further, the compounds of formula (I) may be administered to patientswith symptoms of atherosclerosis of arteries supplying the brain, forinstance a stroke or transient ischaemic attack, in order to reduce therisk of a further, possible fatal, attack.

The compounds of formula (I) may also be used for the treatment ofelevated blood lipids in humans.

Additionally, the compounds of formula (I), as hereinbefore defined, arevaluable for the treatment and prophylaxis of multiple risk factorsknown for cardiovascular diseases, such as hypertension,hypertriglyceridemia and high coagulation factor VII phospholipidcomplex activity. Preferably, the compounds of formula (I) is used forthe treatment of elevated blood lipids in humans.

The compounds of formula (I) and pharmaceutically acceptable salts,solvates, pro-drugs or complexes thereof may be used on their own butwill generally be administered in the form of a pharmaceuticalcomposition in which the compounds of formula (I) (the activeingredient) are in association with a pharmaceutically acceptableadjuvant, diluent or carrier.

The present invention thus also provides a pharmaceutical compositioncomprising a therapeutically effective amount of the compound of formula(I) of the present invention and a pharmaceutically acceptable carrier,diluent or excipients (including combinations thereof).

This is a composition that comprises or consists of a therapeuticallyeffective amount of a pharmaceutically active agent. It preferablyincludes a pharmaceutically acceptable carrier, diluent or excipients(including combinations thereof). Acceptable carriers or diluents fortherapeutic use are well known in the pharmaceutical art. The choice ofpharmaceutical carrier, excipient or diluent can be selected with regardto the intended route of administration and standard pharmaceuticalpractice. The pharmaceutical compositions may comprise as—or in additionto—the carrier, excipient or diluent any suitable binder(s),lubricant(s), suspending agent(s), coating agent(s), solubilisingagent(s).

Pharmaceutical compositions within the scope of the present inventionmay include one or more of the following: preserving agents,solubilising agents, stabilising agents, s wetting agents, emulsifiers,sweeteners, colourants, flavouring agents, odourants, salts compounds ofthe present invention may themselves be provided in the form of apharmaceutically acceptable salt), buffers, coating agents,antioxidants, suspending agents, adjuvants, excipients and diluents.

A pharmaceutical composition according to the invention is preferablyformulated for oral administration to a human or an animal. Thepharmaceutical composition may also be formulated for administrationthrough any other route where the active ingredients may be efficientlyabsorbed and utilized, e.g. intravenously, subcutaneously,intramuscularly, intranasally, rectally, vaginally or topically.

In a specific embodiment of the invention, the pharmaceuticalcomposition is shaped in form of a capsule, which could also bemicrocapsules generating a powder or a sachet. The capsule may beflavoured. This embodiment also includes a capsule wherein both thecapsule and the encapsulated fatty acid composition according to theinvention is flavoured. By flavouring the capsule it becomes moreattractive to the user. For the above-mentioned therapeutic uses thedosage administered will, of course, vary with the compound employed,the mode of administration, the treatment desired and the disorderindicated.

The pharmaceutical composition may be formulated to provide a dailydosage of 10 mg to 10 g. Preferably, the pharmaceutical composition isformulated to provide a daily dosage between 50 mg and 5 g of saidcomposition. Most preferably, the pharmaceutical composition isformulated to provide a daily dosage between 100 mg and 1 g of saidcomposition. By a daily dosage is meant the dosage per 24 hours. Thedosage administered will, of course, vary with the compound employed,the mode of administration, the treatment desired and the disorderindicated. Typically, a physician will determine the actual dosage whichwill be most suitable for an individual subject. The specific dose leveland frequency of dosage for any particular patient may be varied andwill depend upon a variety of factors including the activity of thespecific compound employed, the metabolic stability and length of actionof that compound, the age, body weight, general health, sex, diet, modeand time of administration, rate of excretion, drug combination, theseverity of the particular condition, and the individual undergoingtherapy. The agent and/or the pharmaceutical composition of the presentinvention may be administered in accordance with a regimen of from 1 to10 times per day, such as once or twice per day. For oral and parenteraladministration to human patients, the daily dosage level of the agentmay be in single or divided doses.

A further aspect of the present invention relates to a fatty acidcomposition comprising compounds of formula (I). A fatty acidcomposition comprising compounds of formula (I) increases the naturalbiological effects of DHA that are a result of regulation of geneexpression, and the derivatives according to the present invention willaccumulate in the free fatty acid pool.

The fatty acid composition may comprise in the range of 60 to 100% byweight of the compounds of formula (I), all percentages by weight beingbased on the total weight of the fatty acid composition. In a preferredembodiment of the invention, at least 80% by weight of the fatty acidcomposition is comprised of compounds of formula (I). More preferably,the compounds of formula (I) constitute at least 90% by weight of thefatty acid composition. Most preferably, the compounds of formula (I)constitutes more than 95% by weight of the fatty acid composition.

The fatty acid composition may further comprise at least one of thefatty acids (all-Z)-5,8,11,14,17-eicosapentaenoic acid (EPA),(all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA),(all-Z)-6,9,12,15,18-heneicosapentaenoic acid (HPA), and(all-Z)-7,10,13,16,19-docosapentaenoic acid (DPAn-3),(all-Z)-8,11,14,17-eicosatetraenoic acid (ETAn-3), or combinationsthereof. Further, the fatty acid composition may comprise(all-Z)-4,7,10,13,16-Docosapentaenoic acid (DPAn-6) and/or(all-Z)-5,8,11,14-eicosatetraenoic acid (ARA), or derivatives thereof.The fatty acid composition may also comprise at least these fatty acids,or combinations thereof, in the form of derivatives. The derivatives aresuitably substituted in the same way as the DHA derivatives of formula(I), as hereinbefore defined.

The fatty acid composition according to the invention may comprise(all-Z omega-3)-6,9,12,15,18-heneicosapentaenoic acid (HPA), orderivatives thereof, in an amount of at least 1% by weight, or in anamount of 1 to 4% by weight.

Further, the fatty acid composition according to the invention maycomprise omega-3 fatty acids other than EPA and DHA that have 20, 21, or22 carbon atoms, or derivatives thereof, in an amount of at least 1.5%by weight, or in an amount of at least 3% by weight.

In specific embodiments of the invention, the fatty acid composition isa pharmaceutical composition, a nutritional composition or a dietarycomposition. The fatty acid composition may further comprise aneffective amount of a pharmaceutically acceptable antioxidant.Preferably, the antioxidant is tocopherol or a mixture of tocopherlos.In a preferred embodiment the fatty acid composition further comprisestocopherol, or a mixture of tocopherols, in an amount of up to 4 mg perg of the total weight of the fatty acid composition. Preferably, thefatty acid composition comprises an amout of 0.2 to 0.4 mg per g oftocopherols, based on the total weight of the compositition.

Another aspect of the invention provides a fatty acid composition, orany pharmaceutically acceptable salt, solvate, pro-drug or complexthereof, comprising compounds of formula (I), as hereinbefore defined,for use as a medicament and/or in therapy. Such a fatty acid compositionmay be used to prevent and/or treat the same conditions as outlined forthe compounds of formula (I) above.

When the fatty acid composition is used as a medicament, it will beadministered in a therapeutically or a pharmaceutically active amount.

In a preferred embodiment, the fatty acid composition is administeredorally to a human or an animal.

The present invention also provides the use of a compound of formula(I), or a pharmaceutically acceptable salt, solvate, pro-drug or complexthereof, as hereinbefore defined, for the manufacture of a medicamentfor controlling body weight reduction and/or for preventing body weightgain; for the manufacture of a medicament for the treatment and/or theprevention of obesity or an overweight condition; for the manufacture ofa medicament for the prevention and/or treatment of diabetes in a humanor animal; for the manufacture of a medicament for the treatment and/orprevention of amyloidos-related diseases; for the manufacture of amedicament for the treatment and prophylaxis of multiple risk factorsknown for cardiovascular diseases, such as hypertension,hypertriglyceridemia and high coagulation factor VII phospholipidcomplex activity; for the manufacture of a medicament for the treatmentof TBC or HIV; for the manufacture of a medicament for prevention ofstroke, cerebral or transient ischaemic attacks related toatherosclerosis of several arteries; for the manufacturing of amedicament for lowering triglycerides in the blood of mammals and/orevelating the HDL cholesterol levels in the serum of a human patients;or for the manufacturing of a medicament for the treatment and/orprevention of the multi metabolic syndrome termed “metabolic syndrome”.All these embodiments also include the use of a fatty acid composition,as hereinbefore defined, comprising compounds of formula (I) for themanufacture of medicaments as outlined above. The present inventionfurther relates to the use of alpha-hydroxy-DHA for the manufacture ofmedicaments as outlined above.

The present invention also relates to a method for controlling bodyweight reduction and for preventing body weight gain, wherein a fattyacid composition comprising at least a compound of formula (I), ashereinbefore defined, is administered to a human or an animal.

Further, the invention relates to a method for the treatment and/or theprevention of obesity or an overweight condition, wherein a fatty acidcomposition comprising at least a compound of formula (I), ashereinbefore defined, is administered to a human or an animal.

In a preferred embodiment of the invention, the present inventionrelates to a method for the prevention and/or treatment of diabetesmellitus, wherein a fatty acid composition comprising at least acompound of formula (I), as hereinbefore defined, is administered to ahuman or an animal. Preferably, diabetes mellitus is a type 2 diabetes.

Other aspects of the present invention relate to;

-   -   a method for the treatment and/or prevention of        amyloidos-related diseases;    -   a method for the treatment or prophylaxis of multiple risk        factors for cardiovascular diseases;    -   a method for prevention of stroke, cerebral or transient        ischaemic attacks related to atherosclerosis of several        arteries;        wherein a fatty acid composition comprising at least a compound        of formula (I), as hereinbefore defined, is administered to a        human or an animal.

The fatty acid derivatives of formula (I) may be prepared mosteffectively from DHA. If the start material is not pure DHA (i.e. not100% DHA) the final fatty acid composition will contain a mixture of DHAderivatives, as hereinbefore defined, and an amount of other fatty acidsthan DHA, wherein these fatty acids are substituted in the same way asthe novel fatty acid analogous of formula (I). Such embodiments are alsoincluded herein.

In another embodiment of the invention, the compounds of formula (I) areprepared from (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA),wherein said DHA is obtained from a vegetable, a microbial and/or ananimal source, or combinations thereof. Preferably, said DHA is obtainedfrom a marine oil, such as a fish oil.

The fatty acids in the composition may also be obtained from avegetable, a microbial or an animal source, or combinations thereof.Thus, the invention also includes a fatty acid composition prepared froma microbial oil.

The present invention provides processes for preparing novel fatty acidanalogous of formula (I), as hereinbefore defined.

DHA is produced from biological sources like marine, microbial orvegetable fats. All possible raw materials are mixtures of fatty acidson triglyceride form where DHA constitutes only a fraction of the fattyacids. Typical DHA concetrations are 40% in microbial fats and 10-25% inmarine fats. DHA-containing vegetable fats are during development andfats with high DHA concentrations are expected in the future.

The first process step will always be conversion of the triglycerides tofree fatty acids or monoesters. Preferable esters are methyl or ethylesters, but other esters are possible. In this way the fatty acids boundtogether three by three on triglycerides are separated from each otherand thereby making separation possible. Several methods of separatingDHA from other fatty acids are available, the most common ones beingshort path distillation separating the fatty acids by volatility, andurea precipitation separating the fatty acids by degree of unsaturation.Other methods reported are silver nitrate complexation also separatingthe fatty acids on degree on unsaturation, esterification reactionscatalysed by fatty acid selective lipases in combination with short pathdistillation and countercurrent extraction with supercritical carbondioxide.

The most important challenges connected to production of pure DHA is toseparate it from the other C20-22 highly unsaturated fatty acids presentin all available sources. These fatty acids have properties so similarto DHA that none of the methods mentioned above provide sufficientdegree of separation. For some microbial high DHA fats, which have verylow levels of C20-22 highly unsaturated fatty acids, short pathdistillation alone or in combination of other methods mentioned mayprovide more that 90% purity.

Most DHA containing fats also contain considerable amounts of C20-22highly unsaturated fatty acids, e.g. EPA (20:5n-3), n-3DPA (22:5n-3),HPA (21:5n-3) and others. The only available method for separating DHAfrom such fatty acids is preparative High Performance LiquidChromatography, the stationary phase being silica gel or silver nitrateimpregnated silica gel, the moblie phase being selected organic solventsor supercritical carbon dioxide. With this method DHA with more than 97%purity is available. However, it has to be noted that the productioncosts increases strongly with concentration, as an example is productioncost for 97% DHA more 5 times higher than for 90% DHA.

DHA having a purity of 90, 95 eller 97% contains small amounts of otherfatty acids. As an example, DHA having a purity of 97% contains n-3DPA(22:5n-3), but also long chain fatty acids, e.g. EPA (20:5n-3), HPA(21:5n-3), and others. However, the other fatty acids will react in away similar to DHA and provide alpha-substituted derivatives.

Organic synthesis may provide a purification method since DHA and n-6DPA(and 22:5n-6 which normally is present in very low concentrations) arethe only known fatty acids that can provide gamma-lactones bycyclisation with the first double bond. Lactonisation followed bypurification and hydrolysis back to DHA may be a possibility, but it isexpected that this pathway is even more expensive than HPLC.

In one embodiment, the compounds of formula (I) where R₁ (or R₂) is ahydrogen are prepared through the following processes (Scheme 1).Suitably adapted, these processes can alsoe be used for preparingcompounds represented by the general formula (I) where both R₁ and R₂are e.g. a C₁-C₇ alkyl group, a benzyl, a halogen, a benzyl, an alkenyl,or an alkynyl.

Compounds represented by the general formula (I) where R₁ is a hydrogenand R₂ denotes a C₁-C₇ alkyl group, a benzyl, a halogen, a benzyl, analkenyl, an alkynyl are prepared by reacting a DHA ester with a strongnon-nucleophilic base like lithium diisopropylamine or potassium/sodiumhexamethyldisilazideane in a solvent such as tetrahydrofuran,diethylether at temperatures of −60 to −78° C., to provide the esterenolate (process 1).

This ester enolate is reacted with an electrophilic reagent like analkylhalide exemplified by ethyliodine, benzylcloride, an acyl halideexemplified by acetyl chloride, benzoyl bromide, a carboxylic anhydrideexemplified by acetic anhydride or a electrophilic halogenation reagentexemplified by N-fluorobenzene sulfonimide (NFSI), etc. to provide themonosubstitued derivative (process 2). The ester is further hydrolysedin a solvent like ethanol or methanol to the carboxylic acid derivativeby addition of a base like lithium/sodium hydroxide in water attemperatures between 15-40° C.

Claisen condensation of the DHA EE occurs during the treatment of DHA EEwith a strong base. This condensation product might possess interestingbiologically activity. Thus, in one embodiment of the invention thecondensation (intermediate) product mentioned above, as well as the useof this product for treatment and/or prevention of diseases according tothe present invention, are disclosed.

In a further embodiment, compounds represented by the general formula(I) are synthesised through following processes (Scheme 2).

Compounds represented by the general formula (I) where R₁ is a hydrogenand R₂ denotes a hydroxy, an alkoxy group, an acyloxy are prepared byreacting a DHA ester with a strong non-nucleophilic base like lithiumdiisopropylamine or potassium/sodium hexamethyldisilazane in a solventsuch as tetrahydrofuran, diethylether at temperatures of −60 to −78° C.,to provide the ester enolate (process 4). This ester enolate is reactedwith an oxygen source like dimethyldioxirane,2-(phenylsulfonyl)-3-phenyloxaziridine, molecular oxygen with differentadditives like trimethylphosphite or different catalysts like a Ni(II)complex to provide alpha-hydroxy DHA ester (process 5). Reaction of thesecondary alcohol with a base like sodiumhydride in a solvent like THFor DMF generates an alkoxide that is reacted with differentelectrophilic reagents as alkyliodide for example; methyl iodide, ethyliodide, benzylbromide or an acyl halide, for example; acetyl chloride,benzoyl bromide (process 6). The ester is hydrolysed in a solvent likeethanol or methanol to the carboxylic acid derivative by addition of abase like lithium/sodium hydroxide in water at temperatures between15-40° C. (process 7).

The hydroxy-DHA ester is a useful intermediate for the introduction ofother functional groups in the α-position according to the invention.The hydroxyl function can be activated by conversion to a halide ortosylate prior to reaction with different nucleophiles like ammonia,amines, thiols, etc. The Mitsunobu reaction is also useful for theconversion of a hydroxylgroup into other functional groups. (Mitsunobu,O, Synthesis, 1981, 1).

Compounds represented by the general formula (I), as hereinbeforedefined, can also be synthesised by combinations of the differentprocesses previously described. The present invention includes theprocesses mentioned above.

The invention further provides a process for the preparation of apharmaceutical composition of the invention, with comprises mixing of atleast a compound of formula (I), or a pharmaceutically acceptable salt,solvate, complex or pro-drug thereof, as hereinbefore defined, with apharmaceutically acceptable adjuvant, diluent or a carrier.

The enantiomeric pure compounds can be prepared by resolving a racemiccompound of formula (I), as hereinbefore defined. The resolution of acompound of formula (I) may be carried out using known resolutionprocedures, for example by reacting the compound of formula (I) with anenantiomerically pure auxiliary to provide a mixture of diastereomersthat can be separated by chromatography. Thereafter the two enantiomersof compound (I) may be regenerated from the separated diastereomers byconventional means, such as hydrolysis.

There is also a possibility to use stochiometric chiral auxiliaries toeffect an asymmetric introduction of the substituents, as hereinbeforedefined, in the α-position of DHA. The use of chiral oxazolidin-2-oneshas proved to be a particularly effective methodology. The enolatesderived from chiral N-acyloxazolidines can be quenched with a variety ofelectrophiles in a highly stereoregulated manner (Ager, Prakash, Schaad1996).

EXAMPLES

The invention will now be described in more detail by the followingexamples, which are not to be constructed as limiting the invention. Inthe examples the structures were verified by Mass Spectrometry (MS). Itshould be pointed out that the fatty acid derivatives may also beproduced from low and medium DHA-containing starting material (i.e.about 40-60 w % DHA).

Synthesis Protocols

Preparation of α-methyl DHA EE (PRB-1)

Butyllithium (228 ml, 0.37 mol, 1.6 M in hexane) was added dropwise to astirred solution of diisopropylamine (59.5 ml, 0.42 mol) in dry THF (800ml) under N₂ at 0° C. The resulting solution was stirred at 0° C. for 30min., cooled to −78° C. and stirred an additional 30 min. beforedropwise addition of DHA EE (100 g, 0.28 mol) in dry THF (500 ml) during2 h. The dark-green solution was stirred at −78° C. for 30 min. beforeMeI (28 ml, 0.45 mol) was added. The solution was allowed to reach −20°C. during 1.5 h, then poured into water (1.5 l) and extracted withheptane (2×800 ml). The combined organic phases were washed with 1 M HCl(1 l), dried (Na₂SO₄), filtered and evaporated in vacuo. The product waspurified by dry flash chromatography on silica gel eluting withheptane/EtOAc (99:1) to give 50 g (48%) of the titled compound as aslightly yellow oil;

¹H-NMR (200 MHz, CDCl₃) δ1.02 (t, J 7.5 Hz, 3H), 1.20 (d, J 6.8 Hz, 3H),1.29 (t, J 7.1 Hz, 3H), 2.0-2.6 (m, 5H), 2.8-3.0 (m, 10H), 4.17 (t, J7.1 Hz, 2H), 5.3-5.5 (m, 12H);

MS (electrospray); 393 [M+Na].

Preparation of α-ethyl DHA EE (PRB-2)

Butyllithium (440 ml, 0.67 mol, 1.6 M in hexane) was added dropwise to astirred solution of diisopropylamine (111 ml, 0.78 mol) in dry THF (750ml) under N₂ at 0° C. The resulting solution was stirred at −78° C. for45 min. before dropwise addition of DHA EE (200 g, 0.56 mol) in dry THF(1.6 l). The addition of the ester was complete in 4 hours. Thedark-green solution was stirred at −78 ° C. for 30 min. before EtI (65ml, 0.81 mol) was added. The solution was allowed to reach −40° C.before an additional amount of EtI (5 ml, 0.06 mol) was added, andfinally reach −15° C. (during 3 hours from −78° C.) before the mixturewas poured into water and extracted with hexane (2×). The combinedorganic phases were washed with 1 M HCl, water, dried (Na₂SO₄), filteredand evaporated in vacuo. The product was purified by flashchromatography on silica gel eluting with heptane/EtOAc (99:1 followedby 50:1) to give 42.2 g (20%) of the titled compound as a yellow oil;

¹H-NMR (200 MHz; CDCl₃) δ 0.8-1.0 (m, 6H), 1.2-1.4 (m, 4H), 1.5-1.7 (m,2H), 2.12 (m, 2H), 2.3-2.5 (m, 2H), 2.8-3.0 (m, 10H), 4.18 (t, J 7.1 Hz,2H), 5.3-5.6 (m, 12H);

MS (electrospray); 407 [M+Na].

Preparation of α-ethoxy-DHA ethylester (PRB-3)

To a suspension of 60% NaH (84.1 mg, 2.1 mmol) in THF, 5 mL, at −78° C.under N₂-atmosphere was added drop wise a solution of α-hydroxy-DHAethyl ester (PRB-12) (372 mg, 1.00 mmol) in THF, 5 mL, the resultingmixture was stirred at −78° C. for 20 minutes before ethyl iodide (0.24mL, 3.01 mmol) was added drop wise. The reaction mixture was graduallywarmed to room temperature over night. Saturated aqueous NH₄Cl, 15 mL,was added and the mixture was extracted with diethyl ether, 25 mL×2, theorganic phase was washed with brine, 25 mL, dried (Na₂SO₄) filtered,evaporated in vacuo and subjected to flash chromatography on silica geleluting with heptane/EtOAc (95:5) to yield 68 mg (17%) of the product asa yellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.94 (t, J=7.5 Hz, 3H), 1.16-1.29 (m, 6H),2.05 (quint, J=7.2 Hz, 2H), 2.50 (m, 2H), 2.76-2.84 (m, 10H), 3.33-3.48(m, 1H), 3.53-3.71 (m, 1H), 3.83 (dd, J=6.8 Hz, J=6.2 Hz, 1H), 4.18 (q,J=7.1 Hz, 2H), 5.31-5.45 (m, 12H)

¹³C NMR (50 MHz, CDCl₃) δ14.2, 15.1, 20.5, 25.5, 25.6, 25.7, 31.0, 60.8,66.0, 78.7, 124.1, 127.0, 127.8, 127.9, 128.0 (2 signals), 128.2 (2signals), 128.5, 130.7, 132.0, 172.5 (3 signals hidden)

MS (electrospray); 423 [M+Na]⁺

Preparation of α-fluoro DHA EE (PRB-4)

LDA (2.1 ml, 4.2 mol, 2 M in THF/heptane/ethylbenzene) in dry THF (10ml) under N₂ at −78° C. was dropwise added DHA EE (1 g, 2.8 mmol) in dryTHF (30 ml) during 15 min. NFSi (1.06 g, 3.4 mmol) was then added. Thesolution was allowed to reach RT and stirred for 70 hours. The mixturewas poured into water and extracted with hexane (2×). The combinedorganic phases were washed with 1 M HCl, water, dried (Na₂SO₄), filteredand evaporated in vacuo; MS (electrospray); 397 [M+Na].

Preparation of α,α-dimethyl DHA EE (PRB-5)

Butyllithium (100 ml, 0.17 mol, 1.6 M in hexane) was added dropwise to astirred solution of diisopropylamine (28 ml, 0.20 mol) in dry THF (100ml) under N₂ at 0° C. The resulting solution was stirred at 0° C. for 30min., cooled to −78° C. and dropwise added a solution of DHA EE (50 g,0.14 mol) in dry THF (200 ml). The resulting dark-green solution wasstirred at −78° C. for 30 min. before MeI (17 ml, 0.28 mol) was added.The solution was allowed to reach −10° C., then poured into water andextracted with hexane (2×). The combined organic phases were washed with1 M HCl, dried (Na₂SO₄), filtered and evaporated in vacuo.

The procedure was repeated, but the crude product of α-methyl DHA EE wasused instead of DHA EE. The product was purified by dry flashchromatography on silica gel eluting with heptane/EtOAc (99:1 followedby 98:2) to give 31.6 g (59%) of the titled compound as a slightlyyellow oil;

¹H-NMR (200 MHz; CDCl₃) δ 1.01 (t, J 7.5 Hz, 3H), 1.21 (s, 6H), 1.28 (t,J 7.1 Hz, 3H), 2.08 (m, 2H), 2.34 (d, J 6.8 Hz, 2H), 2.8-3.0 (m, 10H),4.15 (q, J 7.5 Hz, 2H), 5.3-5.6 (m, 12H);

¹³C-NMR (50 MHz; CDCl₃) δ 14.7, 21.0, 25.3, 26.0, 26.1, 38.3, 42.8,60.7, 125.8, 127.4, 128.3, 128.5, 128.6, 128.7, 129.0, 130.7, 132.4,177.9;

MS (electrospray); 385 [M+H].

Preparation of α-thiomethyl DHA (PRB6)

α-Iodo DHA EE (0.5 g, 1.04 mmol) dissolved in 20 mL THF at 0° C. underN₂. MeSNa (80 mg, 1.14 mmol) was added the reaction and the mixture wasallowed to stir for a few minutes before it was diluted with heptane.The organic phase was washed with water (2×) dried (Na₂SO₄) andevaporated in vacuo. The desired product was was isolated by flashchromatography Heptan/EtOAc (30:1) to give α-thiomethyl DHA EE as a paleyellow oil. The α-thiomethyl DHA EE was dissolved in 10 mL EtOH and 10mL THF. The solution was added LiOH (0.39 g, 9.2 mmol) dissolved in 5 mLwater. The reaction mixture was allowed to stir overnight at RT, beforediluting with water and heptane. The organic fraction was extracted with1M LiOH (2×) and the combined aqueous phases was acidified with 5M HCland extracted with diethyl ether (2×). The combined organic phases waswashed with brine, water, dried (Na₂SO₄) and evaporated in vacuo to give183 mg (47%) of the title compound as a pale yellow oil;

¹H-NMR (200 MHz, CDCl₃) δ 0.98 (t, J 6.6 Hz, 3H), 1.95-2.65 (m, 7H),2.72-3.05 (m, 10H), 3.12-3.43 (m, 1H), 5.20-5.70 (m, 12H), 10.65 (br s,1H);

¹³H-NMR (50 MHz, CDCl₃) δ 14.7, 21.0, 25.9, 26.0, 26.2, 28.8, 125.4,127.4, 128.1, 128.3, 128.4, 128.7, 128.9, 129.0, 131.6, 132.4, 177.0.

Preparation of α-thioethyl DHA EE (PRB-7)

α-Iodo DHA EE (11 g, 23 mmol) dissolved in 100 mL THF under N₂ at 0° C.EtSNa (2.1 g, 25 mmol) was added the solution and was allowed to stirfor 1 hour at 0° C. The reaction was quenched with 1M HCl and dilutedwith Heptan. The organic phase was washed with water (2×), dried(Na₂SO₄) and evaporated in vacuo. The desired product was isolated byflash chromatography Heptan/EtOAc (30:1) to give 7.3 g (76%) of thetitle compound as a pale yellow oil;

¹H-NMR (200 MHz, CDCl₃) δ 1.1-1.3 (m, 9H), 2.05 (m, 2H), 2.3-2.7 (m,4H), 2.7-2.9 (m, 10H), 3.25 (m, 1H), 4.17 (q, J 7.1 Hz, 2H), 5.3-5.5 (m,12H);

MS (electrospray): 439 [M+Na].

Preparation of α,α-diethyl DHA EE (PRB-8):

Butyllithium (38.6 ml, 0.62 mol, 1.6 M in hexane) was added dropwise toa stirred solution of diisopropylamine (9.1 ml, 0.65 mol) in dry THF(200 ml) under N₂ at 0° C. The resulting solution was stirred at 0° C.for 30 min., cooled to −78° C. and dropwise added a solution of DHA EE(20.0 g, 0.56 mol) in dry THF (100 ml). The resulting dark-greensolution was stirred at −78° C. for 30 min., before EtI (6.8 ml, 0.84mol) was added. The solution was allowed to reach −10° C., then pouredinto water and extracted with hexane (2×). The combined organic phaseswere washed with 1 M HCl, dried (Na₂SO₄), filtered and evaporated invacuo.

The procedure was repeated, but the crude product of α-ethyl DHA EE wasused instead of DHA EE. The reaction mixture after addition of EtI wasallowed to reach ambient temperature and was stirred over night. Theproduct was purified by dry flash chromatography on silica gel elutingwith heptane/EtOAc (99:1 followed by 98:2) to give 10.0 g (43%) of thetitled compound as a slightly yellow oil;

¹H-NMR (200 MHz; CDCl₃) δ 0.83 (t, J 7.4 Hz, 6H), 0.94 (t, J 5.8 Hz,3H), 1.28 (t, J 7.1 Hz, 3H), 1.63 (q, J 7.4 Hz, 4H), 2.10 (m, 2H), 2.34(d, J 6.9 Hz, 2H), 2.8-3.0 (m, 10H), 4.15 (q, J 7.5 Hz, 2H), 5.3-5.6 (m,12H);

¹³C-NMR (50 MHz; CDCl₃) δ 8.9, 14.7, 21.0, 23.1, 25.9, 26.0, 26.2, 27.4,31.2, 50.1, 60.6, 125.5, 127.4, 128.3, 128.6, 128.9, 130.5, 132.4,177.1;

MS (electrospray); 413.3 [M+H], 435.3 [M+Na].

Preparation of α-benzyl DHA EE (PRB-9):

To a stirred solution of diisopropyl amine (0.91 mL, 6.46 mmol) in dryTHF (20 mL) under inert atmosphere held at 0° C. was added drop wisen-BuLi (1.6 M in hexanes, 3.86 mL, 6.18 mmol). The mixture was stirredat 0° C. for 30 minutes, given −78° C. and stirred at this temperaturefor five minutes. DHA EE (2.0 g, 5.62 mmol) in dry THF (10 mL) was addeddrop wise and the mixture was stirred at −78° C. for 20 minutes, thenbenzyl bromide (0.80 mL, 6.74 mmol) was added. The resulting solutionwas allowed to reach 0° C. over three hours, portioned between water(100 mL) and heptane (100 mL). The aqueous layer was extracted withheptane (50 mL) and the combined organic layer was washed with 1M HCland dried (Na₂SO₄). Concentration under reduced pressure andpurification by flash chromatography (Heptane:EtOAc 99:1) afforded 1.05g (42%) of the title compound as a colorless oil;

¹H-NMR (200 MHz, CDCl₃): δ 0.99 (t, 3H), 1.18 (t, 3H), 2.08-2.16 (m,2H), 2.35-2.42 (m, 2H), 2.74-2.98 (m, 13H), 4.09 (q, 4H), 5.38-5.50 (m,10H), 7.19-7.36 (m, 5H);

¹³C-NMR (50 MHz, CDCl₃): δ 14.61, 14.71, 20.99, 25.98, 26.07, 30.07,38.32, 48.02, 60.88, 126.75, 126.83, 127.46, 128.31, 128.45, 128.53,128.58, 128.86, 128.77, 129.01, 129.35, 130.55, 132.46, 138.89, 175.39.

MS (electrospray): 447.3 [M+H], 469.3 [M+Na].

Preparation of α-ethanesulfinyl DHA EE (PRB-10)

To a solution of α-thioethyl DHA EE (0.5 g, 1.3 mmol) in 15 mL CHCl₃held at −20° C. under inert atmosphere was added a solution of MCPBA(0.22 g, 1.3 mmol) in 10 mL CHCl₃. The reaction mixture was stirred for2 h at this temperature, filtered and washed with a saturated aqueoussolution of NaHCO₃. The aqueous phase was extracted twice with CHCl₃ andthe combined organic phase was washed with water and brine, dried withNa₂SO₄, filtered and concentrated. The product was isolated fromresidual material after flash chromatography using hexane:EtOAc 8:2 toafford 0.35 g (70%) of the title compound.

¹H NMR (200 MHz, CDCl₃): δ 0.99 (t, 3H), 1.27-1.45 (m, 6H), 2.09 (m,2H), 2.79-2.94 (m, 14H), 3.55 (m, 1H), 4.25 (q, 2H), 5.37-5.59 (m, 12H).

¹³C NMR (50 MHz, CDCl₃): δ 7.97, 14.58, 14.68, 20.95, 23.68, 25.17,25.93, 26.04, 44.20, 45.15, 62.30, 64.08, 123.91, 124.47, 127.41,127.86, 128.26, 128.40, 128.44, 128.72, 128.72, 128.96, 129.12, 132.42,132.47, 174.55.

MS (electrospray): 455.3 [M+Na].

Preparation of α-thiophenyl-DHA ethylester (PRB-11)

To a solution of α-iodo-DHA ethylester (PRB-15) (3.40 g, 7.05 mmol) inacetone, 20 mL, a solution of sodium phenyl sulfide (1.039 g, 7.86 mmol)in acetone, 110 mL, was added drop wise. The resulting mixture wasstirred at ambient temperature for 1½ hrs, evaporated in vacuo andsubjected to flash chromatography on silica gel eluting withheptane/EtOAc 200:1-95:5 to yield 2.35 g (72%) of the product as ayellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.97 (t, J=7.5 Hz, 3H), 1.18 (t, J=7.1 Hz,3H), 2.09 (quint, J=7.1 Hz, 2H), 2.54-2.66 (m, 2H), 2.83-2.86 (m, 10H),3.67 (dd, J=6.8 Hz, J=8.3 Hz, 1H), 4.12 (q, J=7.1 Hz, 2H), 5.24-5.49 (m,12H), 7.28-7.33 (m, 3H), 7.46-7.50 (m, 2H)

¹³C NMR (50 MHz, CDCl₃) δ 14.0, 14.2, 20.5, 25.5, 25.6, 25.7, 29.4,50.6, 61.1, 125.1, 127.0, 127.7, 127.9, 128.0, 128.3, 128.42, 128.45,128.9, 131.2, 132.0, 133.0, 133.2, 174.1 (5 signals hidden)

MS (electrospray); 465 [M+H]⁺, 487 [M+Na]⁺

HRMS (EI) calculated for C₃₀H₄₀O₂S: 464.2749, found: 464.2741

Preparation of α-hydroxy-DHA ethylester (PRB-12)

To a solution of diisopropyl amine (19.76 mL, 140 mmol) in dry THF, 40mL, under N₂-atmosphere at −78° C. was added drop wise 1.6 M BuLi inhexane (87.5 mL, 140 mmol). The resulting mixture was stirred at −78° C.for 15 minutes before a solution of DHA ethylester (24.99 g, 70.1 mmol)in THF, 80 mL, was added drop wise. The resulting dark green reactionmixture was stirred for 1 hour at −78° C. before triethylphosphite (12.2mL, 70.1 mmol) was added drop wise and then O₂ was bubbled through thereaction mixture over night while the reaction mixture was kept at −78°C. for 5 hrs and then slowly warmed to room temperature. Saturatedaqueous NaHCO₃, 100 mL, was added and the mixture was extracted withdiethyl ether, 200 mL×2. The organic phase was dried (Na₂SO₄), filteredand evaporated in vacuo and subjected to flash chromatography on silicagel eluting with heptane/EtOAc 99:1-95:5 to yield 4.52 g (17%) of theproduct as a yellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.92 (t, J=7.5 Hz, 3H), 1.24 (t, J=7.1 Hz,3H), 2.02 (quint, J=7.1 Hz, 2H), 2.44-2.54 (m, 2H), 2.74-2.87 (m, 10H),4.13-4.24 (m, 3H), 5.25-5.94 (m, 12H)

¹³C NMR (50 MHz, CDCl₃) δ 14.0, 14.1, 20.4, 25.4, 25.5, 25.6, 32.0,61.5, 69.9, 123.3, 126.9, 127.7, 127.9, 128.08, 128.1, 128.2, 128.4,131.3, 131.8, 174.4 (4 signals hidden)

MS (electrospray); 395 [M+Na]⁺

HRMS (ES) calculated for C₂₄H₃₆O₃Na: 395.2556, found: 395.2543

Preparation of α-methyl-DHA amide (PRB-13)

A solution of α-methyl-DHA (PRB-1 FA) (3.13 g, 9.1 mmol) and oxalylchloride (8.0 mL, 94.5 mmol) in toluene, 90 mL, was added DMF, 0.1 mL,and the resulting mixture was stirred at ambient temperature underN₂-atmosphere for 15½ hours. The mixture was then evaporated in vacuoand the residue was dissolved in THF, 100 mL, cooled to 0° C. andaqueous NH₃ (20 mL) was added drop wise. The ice-bath was removed andthe mixture was stirred at ambient temperature for 4 hours, water, 50mL, was added and the aqueous phase was extracted with diethyl ether,2×100 mL. The organic phase was washed with saturated aqueous NH₄Cl, 50mL, dried (Na₂SO₄), filtered and evaporated in vacuo and subjected toflash chromatography on silica gel eluting with CH₂Cl₂/2M NH₃ in MeOH97.5:2.5 to yield 2.51 g (80%) of the product as a yellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.91 (t, J=7.5 Hz, 3H), 1.10 (d, J=9.8 Hz,3H), 1.94-2.11 (m, 3H), 2.19-2.35 (m, 2H), 2.76-2.77 (m, 10H), 5.18-5.45(m, 12H), 6.03 (s, 1H), 6.72 (s, 1H)

¹³C NMR (50 MHz, CDCl₁₃) δ 14.6, 17.6, 20.8, 25.8, 25.9, 32.0, 41.0,127.3, 128.1, 128.4, 128.6, 128.8, 130.1, 132.2, 179.6 (8 signalshidden)

MS (electrospray); 342 [M+H]⁺, 364 [M+Na]⁺

HRMS (EI) calculated for C₂₃H₃₅NO: 341.2719, found: 341.2707

Preparation of α-methoxy-DHA ethylester (PRB-14)

To a suspension of 60% NaH (61.1 mg, 1.53 mmol) in THF, 5 mL, at −78° C.under N₂-atmosphere was added drop wise a solution of α-hydroxy-DHAethyl ester (PRB-12) (373 mg, 1.00 mmol) in THF, 5 mL, the resultingmixture was stirred at −78° C. for 20 minutes before methyl iodide (0.13mL, 2.09 mmol) was added drop wise. The reaction mixture was graduallywarmed to room temperature for 5 hrs. Saturated aqueous NH₄Cl, 15 mL,was added and the mixture was extracted with diethyl ether, 25 mL×2, theorganic phase was washed with brine, 25 mL, dried (Na₂SO₄) filtered,evaporated in vacuo and subjected to flash chromatography on silica geleluting with heptane/EtOAc 99:1-4:1 to yield 136 mg (35%) of the productas a yellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.92 (t, J=7.5 Hz, 3H), 1.24 (t, J=7.1 Hz,3H), 2.03 (quint, J=7.3 Hz, 2H), 2.48 (t, J=5.7 Hz, 2H), 2.73-2.82 (m,10H), 3.34 (s, 3H), 3.74 (t, J=6.2 Hz, 1H), 4.17 (q, J=7.1 Hz, 2H),5.24-5.43 (m, 12H)

¹³C NMR (50 MHz, CDC₁₃) δ 14.1, 20.4, 25.4, 25.5, 25.7, 30.6, 57.9,60.9, 80.8, 123.7, 126.9, 127.71, 127.73, 127.92, 127.94, 128.07, 128.1,128.2, 128.4, 130.7, 131.8, 171.9 (3 signals hidden)

MS (electrospray); 409 [M+Na]⁺

HRMS (ES) calculated for C₂₅H₃₈O₃Na: 409.2713, found: 409.2711

Preparation of α-iodo DHA EE (PRB-15)

Diisopropylamine (20 mL, 140 mmol) was dissolved in 150 mL THF under N₂at −20° C. n-BuLi (88 mL, 140 mmol, 1.6 M) was added dropwise to themixture before the solution was cooled to −78° C. DHA EE (50 g, 140mmol) in 250 mL THF was added dropwise to the solution and the reactionmixture was stirred for 30 min at RT. The resulting mixture was addeddropwise to a solution of I₂ (42.8 g, 169 mmol) in 400 mL THF under N₂at −78° C. The reaction was quenched with 1M HCl and diluted withHeptan. The organic phase was washed with 10% Na₂S₂O₃ (2×), dried(Na₂SO₄), filtered and evaporated in vacuo. The desired product wasisolated by flash chromatography Heptan/EtOAc (100:1) to give 11.0 g(16%) of the title compound as a pale yellow oil; MS (Electrospray): 505[M+Na].

Preparation of α-iodo-DHA ethylester (PRB-15)

To a solution of diisopropyl amine (42 mL, 298 mmol) in dry THF, 150 mL,under N₂-atmosphere at −78° C. was added drop wise 1.6 M BuLi in hexane(158 mL, 253 mmol). The resulting mixture was stirred at −78° C. for 35minutes before a solution of DHA ethylester (75.05 g, 210 mmol) in THF,300 mL, was added drop wise. The resulting dark green reaction mixturewas stirred for 30 minutes at −78° C. before a solution of I₂ (91.06 g,359 mmol) in THF, 200 mL was added drop wise. The reaction mixture wasstirred at −78° C. for 20 minutes before it was quenched with water, 200mL, and extracted with heptane, 300 mL. The organic phase was washedwith 1 M HCl, 150 mL, and water, 200 mL, dried (Na₂SO₄), filtered andevaporated in vacuo. The resulting crude product was subjected to flashchromatography on silica gel eluting with heptane/EtOAc (100:1) yielding26.14 g (26%) of the product as a yellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.94 (t, J=7.5 Hz, 3H), 1.24 (t, J=7.1 Hz,3H), 2.04 (quint, J=7.1 Hz, 2H), 2.69-2.84 (m, 12H), 4.17 (q, J=7.1 Hz,2H), 4.22 (t, J=7.9 Hz, 1H), 5.24-5.49 (m, 12H)

¹³C NMR (50 MHz, CDCl₃) δ 13.7, 14.2, 25.5, 26.0 (2 signals), 25.8,34.0, 61.7, 126.1, 127.0, 127.4, 127.8, 127.9, 128.0, 128.2, 128.5,128.5, 131.6, 131.9, 170.9 (4 signals hidden)

MS (electrospray); 505 [M+Na]⁺

Preparation of α-amino-DHA etylester (PRB-17)

A solution of α-phtalimide-DHA ethylester (313.5 mg, 0.62 mmol) in EtOH,5 mL, was added hydrazine hydrate (46 μl, 0.95 mmol) and the resultingmixture was refluxed under N₂-atmosphere for 15½ hrs followed byevaporation in vacuo and flash chromatography on silica gel eluting withCH₂Cl₂:7M NH₃ in MeOH (99:1-95:1) to yield 149 mg (64%) of the productas a yellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.91 (t, J=7.5 Hz, 3H), 1.22 (t, J=7.1 Hz,3H), 1.72 (bs, 2H), 2.02 (quint., J=7.2 Hz, 2H), 2.39-2.46 (m, 2H),2.73-2.82 (m, 10H), 3.47 (bs, 1H), 4.13 (q, 2H), 5.23-5.56 (m, 12H)

¹³C NMR (50 MHz, CDCl₃) δ 14.1, 20.4, 25.4, 25.5, 25.6, 54.1, 60.8,124.4, 126.9, 127.7 (2 signals), 127.9, 128.2, 128.3, 128.4, 131.4,131.9, 189.3 (6 signals hidden)

MS (electrospray); 372 [M+H]⁺

Preparation of (S)-(+)-α-ethyl DHA EE (PRB-20)

Synthesis of intermediate PRB-18:

DHA (3.00 g, 18.3 mmol) was dissolved in dry CH₂Cl₂ (120 mL) held at 0°C. under inert atmosphere and added DMAP (2.45 g, 20.1 mmol) and DCC(3.96 g, 19.2 mmol). The mixture was stirred at 0° C. for 20 minutes,added (4R,5S)-(+)-4-methyl-5-phenyl-2-oxazolidinone (3.24 g, 18.3 mmol)and stirred at ambient temperature for 20 hours. Filtration andpurification by flash chromatography (heptane:EtOAc 6:1) afforded 3.00 g(34%) of intermediate PRB-18 as a colorless oil.

¹H-NMR (200 MHz, CDCl₃): δ 0.93-1.05 (t+d, 6H), 2.11 (m, 2H), 2.51 (m,2H), 2.80-3.00 (m, 10H), 3.05 (m, 2H), 4.77 (m, 1H), 5.34-5.68 (m, 12H),5.70 (d, 1H), 7.28.7.32 (m, 2H), 7.37-7.47 (m, 3H).

Synthesis of Intermediate PRB-19

PRB-18 (1.80 g, 3.70 mmol) in dry THF (10 mL) was added drop wise to asolution of LiHMDS (1M in THF, 4.00 mL, 4.00 mmol) in dry THF (15 mL)held at −78° C. under inert atmosphere. The mixture was stirred at −78°C. for 30 minutes, added EtI (0.89 mL, 11.1 mmol) and slowly given 0° C.over one hour. The mixture was then stirred at 0° C. for 18 hours andportioned between saturated NH₄Cl (50 mL) and diethyl ether (50 mL). Theaqueous layer was extracted with diethyl ether (50 mL) and the combinedorganic layer was washed with 0.1 M HCl (50 mL) and brine (50 mL).Drying (Na₂SO₄) and purification by flash chromatography (heptane:EtOAc95:5) afforded 0.52 g (27%) of intermediate PRB-19 as a colorless oil.

¹H-NMR (200 MHz, CDCl₃): δ 0.88-1.01 (m, 9H), 1.64-1.78 (m, 2H), 2.08(m, 2H), 2.31 (m, 1H), 2.48 (m, 1H), 2.87 (m, 10H), 3.87 (m, 1H), 4.75(m, 1H), 5.32 (m, 12H), 5.63 (d, J 7.1 Hz, 1H), 7.32 (m, 2H), 7.42 (m,3H).

¹³C-NMR (50 MHz, CDCl₃): δ 7.26, 11.75, 14.67, 14.98, 20.95, 25.57,25.93, 26.04, 29.93, 44.59, 55.31, 79.10, 125.21, 126.01, 127.17,127.42, 128.27, 128.50, 128.55, 128.67, 128.95, 129.09, 130.35, 132.42,133.80, 153.18, 176.25.

MS (electrospray): 538.2 [M+Na]

PRB-19 (0.25 g, 0.485 mmol) was dissolved in abs EtOH (5 mL) and given0° C. under inert atmosphere. NaOEt (1M in EtOH, 0.54 mL, 0.54 mmol) wasadded and the mixture was stirred at 0° C. for 30 minutes and portionedbetween water and heptane. The aqueous layer was extracted with heptaneand the combined organic layer was washed with 0.1 M HCl and dried.Purification by flash chromatography afforded 0.025 g (13%) of the titlecompound PRB-20 as a colorless oil.

¹H-NMR (200 MHz; CDCl₃) δ 0.8-1.0 (m, 6H), 1.2-1.4 (m, 4H), 1.5-1.7 (m,2H), 2.12 (m, 2H), 2.3-2.5 (m, 2H), 2.8-3.0 (m, 10H), 4.18 (t, 2H),5.3-5.6 (m, 12H).

MS (electrospray); 407 [M+Na].

[α]_(D)+1.7° (c=1.5, ethanol).

Preparation of (R)-(−)-α-ethyl DHA EE (PRB-23)

Synthesis of intermediate PRB-21:

DHA (1.00 g, 3.05 mmol) was dissolved in dry CH₂Cl₂ (20 mL) held at 0°C. under inert atmosphere and added DMAP (0.41 g, 3.35 mmol) and DCC(0.66 g, 3.20 mmol). The mixture was stirred at 0° C. for 20 minutes,added (4S,5R)-(−)-4-methyl-5-phenyl-2-oxazolidinone (0.54 g, 3.05 mmol)and stirred at ambient temperature for 20 hours. Filtration andpurification by flash chromatography (heptane:EtOAc 6:1) afforded 1.08 g(73%) of intermediate PRB-21 as a colorless oil.

¹H-NMR (200 MHz, CDCl₃): δ 0.93-1.05 (t+d, 6H), 2.11 (m, 2H), 2.51 (m,2H), 2.80-3.00 (m, 10H), 3.05 (m, 2H), 4.77 (m, 1H), 5.34-5.68 (m, 12H),5.70 (d, 1H), 7.28.7.32 (m, 2H), 7.37-7.47 (m, 3H).

Synthesis of intermediate PRB-22:

PRB-21 (3.25 g, 6.67 mmol) in dry THF (15 mL) was added drop wise to asolution of LiHMDS (1M in THF, 7.34 mL, 7.34 mmol) in dry THF (35 mL)held at −78° C. under inert atmosphere. The mixture was stirred at −78°C. for 30 minutes, added EtI (1.6 mL, 20.0 mmol) and slowly given 0° C.over one hour. The mixture was then stirred at 0° C. for 18 hours andportioned between saturated NH₄Cl (50 mL) and diethyl ether (50 mL). Theaqueous layer was extracted with diethyl ether (50 mL) and the combinedorganic layer was washed with 0.1 M HCl (50 mL) and brine (50 mL).Drying (Na₂SO₄) and purification by flash chromatography (heptane:EtOAc95:5) afforded 1.50 g (44%) of intermediate PRB-22 as a colorless oil.

¹H-NMR (200 MHz, CDCl₃): δ 0.88-1.01 (m, 9H), 1.64-1.78 (m, 2H), 2.08(m, 2H), 2.31 (m, 1H), 2.48 (m, 1H), 2.87 (m, 10H), 3.87 (m, 1H), 4.75(m, 1H), 5.32 (m, 12H), 5.63 (d, J 7.1 Hz, 1H), 7.32 (m, 2H), 7.42 (m,3H).

¹³C-NMR (50 MHz, CDCl₃): δ 7.26, 11.75, 14.67, 14.98, 20.95, 25.57,25.93, 26.04, 29.93, 44.59, 55.31, 79.10, 125.21, 126.01, 127.17,127.42, 128.27, 128.50, 128.55, 128.67, 128.95, 129.09, 130.35, 132.42,133.80, 153.18, 176.25.

MS (electrospray): 538.2 [M+Na]

PRB-22 (0.25 g, 0.485 mmol) was dissolved in abs EtOH (5 mL) and given0° C. under inert atmosphere. NaOEt (1M in EtOH, 0.54 mL, 0.54 mmol) wasadded and the mixture was stirred at 0° C. for 30 minutes and portionedbetween water and heptane. The aqueous layer was extracted with heptaneand the combined organic layer was washed with 0.1 M HCl and dried.Purification by flash chromatography afforded 0.025 g (13%) of the titlecompound PRB-23 as a colorless oil.

¹H-NMR (200 MHz; CDCl₃) δ 0.8-1.0 (m, 6H), 1.2-1.4 (m, 4H), 1.5-1.7 (m,2H), 2.12 (m, 2H), 2.3-2.5 (m, 2H), 2.8-3.0 (m, 10H), 4.18 (t, 2H),5.3-5.6 (m, 12H);

MS (electrospray); 407 [M+Na].

[α]_(D)-1.3° (c=1.00, ethanol).

Preparation of α-phtalimide-DHA ethylester (PRB-24)

A mixture of the α-hydroxy-DHA ethyl ester (PRB-12) (373.5 mg, 1.00mmol), phtalimide (178 mg, 1.21 mmol) and triphenyl phosphine (313.9 mg,1.20 mmol) in THF, 10 mL, was cooled to 0° C. under N₂-atmosphere beforediisopropyl azodicarboxylate (0.24 mL, 1.24 mmol) was added drop wise.The ice-bath was removed and the reaction mixture was stirred at ambienttemperature for 18 hrs, whereupon it was evaporated in vacuo andsubjected to flash chromatography on silica gel eluting withheptane/EtOAc (99:1-95:1) to yield 323 mg (64%) of the product as ayellow liquid.

¹H NMR (200 MHz, CDCl₃) δ 0.95 (t, J=7.5 Hz, 3H), 1.22 (t, J=7.1 Hz,3H), 2.05 (m, 2H), 2.72-2.84 (m, 11H), 3.02-3.22 (1H), 4.20 (q, J=7.1Hz, 2H), 4.87 (dd, J=11 Hz, J=4.9 Hz, 1H), 5.17-5.40 (m, 12H), 7.68-7.75(m, 2H), 7.79-7.85 (m, 2H)

¹³C NMR (50 MHz, CDCl₃) δ 14.0, 14.1, 20.4, 25.4, 25.4, 25.5, 27.0,51.8, 61.7, 123.8, 124.3, 126.9, 127.5, 127.7, 127.9, 127.9, 128.1,128.1, 128.3, 128.4, 131.6, 131.8, 131.8, 134.0, 167.3, 168.7 (2 signalshidden)

MS (electrospray); 502 [M+H]⁺, 524[M+Na]⁺

Preparation of α-ethylamino-DHA etylester (PRB-25) andα-diethylamino-DHA etylester (PRB-26)

A mixture of the α-amino-DHA ethylester (PRB-17) (746.5 mg, 2.01 mmol),LiOH.H₂O (171.6 mg, 4.09 mmol) and molsieve 4 Å (599 mg) in DMF, 4 mL,was added ethylbromide (3.0 ml, 40.2 mmol) and the resulting mixture wasstirred at ambient temperature for 71 hrs. The mixture was diluted withdiethyl ether, 100 mL, and filtered. The organic phase was washed with 1M NaOH, 20 mL, and brine, 20 mL, dried (Na₂SO₄), filtered and evaporatedin vacuo and subjected to flash chromatography on silica gel elutingwith heptane:EtOAc (95:5)-CH₂Cl₂:2M NH₃ in MeOH (99:1) to yield 458 mg(53%) of PRB-26 as a yellow liquid and 152 mg (19%) of PRB-25 as ayellow liquid.

PRB-26:

¹H NMR (200 MHz, CDCl₃) δ 0.89 (t, J=7.5 Hz, 3H), 1.03 (t, 3H), 1.24 (t,J=7.1 Hz, 6H), 2.05 (quint, J=7.1 Hz, 2H), 2.52 (m, 4H), 2.76-2.85 (m,12 H), 3.35 (t, 1H), 4.13 (q, J=7.1 Hz, 2H), 5.28-5.44 (m, 12H)

¹³C NMR (75 MHz, CDCl₃) δ 14.1, 14.3, 14.4, 20.5, 22.6, 25.5, 25.6,25.7, 31.9, 44.4, 60.1, 62.9, 127.0, 127.8, 128.05, 128.13, 128.17,128.22, 128.5, 132.0, 173.3 (5 signals hidden)

EXAMPLES

An overview of the models and methods used in the present invention fordemonstrating effects on the metabolic syndrome and type 2 diabetes arepresented in FIG. 2. Five blocks of experiments have been performed inorder to elucidate the effects of DHA derivatives for reduction ofinsulin resistance and/or alleviating the metabolic syndrom. Theinvention shall not be limited to the shown embodiments and examples.

Example 1 Analysis of Intracellular Free Fatty Acids (Non-EsterifiedFatty Acids) in Liver Cells (Block 1 in FIG. 2)

Background

In the first block of experiments (see FIG. 2) liver tissue from animalsfed PRB-1,2,5, and 7 was analysed with respect to free unesterifiedfatty acids. The animals were recruited from the fifth block ofexperiments (pharmacodynamic effects of DHA derivatives in an animalmodel of metabolic syndrome). The animals had been given DHA (15% of fatcontent of the diet) or the DHA-derivatives (1.5% of the fat content intheir diet) for 8 weeks and were supposed to be in a steady-statesituation with stable levels of DHA and the DHA-derivativesintracellularily. Liver tissue was chosen due to the fact that themetabolisation rate is very high in liver.

Method

The liver samples were homogenized in cold PBS buffer, and extractedimmediately with chloroform:methanol (2:1) containing 0.2 mM butylatedhydroxytoluene (BHT) using cis-10-heptadecenoic acid as internalstandard. The organic phases were dried under nitrogen, re-dissolved inacetonitrile with 0.1% acetic acid and 10 μM BHT for RP-HPLC MS/MSanalysis. Total protein content was measured using Bio-Rad method afterhomogenization.

Agilent 1100 system was used for reverse phase column (Supelco AscentisC₁₈ column, 25 cm×4.6 mm, i.d. 5 μm) separation of DHA and its PRBderivatives within 22 min. The flow phase was iso-gradientacetonitrile-H₂O (87+13, v/v) containing 0.1% acetic acid. The columnoven temperature was set at 35° C. The column elute was identified andquantified in the negative electrospray ionisation applying multiplereaction monitoring mode by triple tandem quadrapole mass/mass (ABIQtrap-4000). The parent-daughter ion pairs were 327.3/327.3 (DHA),341.3/341.3 (PRB-1), 355.3/355.3 (PRB-2 and PRB-5), 387.3/387.3 (PRB-7),267.2/267.2 (I.S. FA 17:1) respectively under unit resolution. Thesignal collection dwell time was all 100 msec except for FA 17:1 whichwas set at 200 msec. Accurate verification of isomeric PRB compounds wasdone by combination of the retention time and characteristic mass/chargeratio. The quadratic regression standard curve was used forquantification after internal standard calibration.

Results

Concentration of the different DHA-derivatives and the concentrations ofDHA was given as μg per g of total amount of protein in the liver cells.FIG. 3 depicts the concentrations of the different PRBs from animalsgiven PRB-1, 2, 5 and 7 in a concentration of 1.5% of total fat contentin the high fat diet.

The highest intracellular concentration of the PRBs was obtained forPRB-2. Also PRB-5 was enriched intracellularily, although not to thesame extent as PRB-2. This finding is unexpected.

FIG. 4 depicts the intracellular concentrations of DHA in liver tissuefrom animals given the different PRBs. DHA reached a significantlyhigher level in the animals given PRB-7 compared to the other threeDHA-derivatives. Animals given PRB-2 had the lowest concentration ofDHA. It seems that PRB-7 is to some extent converted back to DHA.

PRB-2 reached the highest intracellular concentration. This means thatPRB-2 will be more available as a ligand to nuclear receptors, a patternwhich could be translated into therapeutic effects in handling of bloodglucose and blood lipids.

Example 2 Computer Based Affinity Testing (Block 2 in FIG. 2)

Background

Nuclear receptors have been sequenced and the amino acid sequence isknown for the PPARs and other relevant receptors engaged in the geneticcontrol of glucose and fat. X-ray crystallography and NMR spectroscopyof the PPAR receptors are available and computerised affinity testing offatty acids liganding to the receptors can be used to estimate bindingkinetics. The binding geometries, often called binding modes or poses,include both positioning of the ligand relative to the receptor and theconformational state of the ligand and the receptor. Effective liganddocking can therefore be analysed.

Affinity of the ligand to the receptor is defined by two differentparameters: docking of the ligand (DHA derivative) into the binding siteof the receptor and electrostatic bonding between certain amino acids ofthe receptor and the carboxyl group or side chains in the head of thefatty acid. (Krumrine).

As previously known, the PPARα receptor is more promiscuous compared toPPARγ, meaning that PPARα will accept more fatty acids as ligandscompared to PPARγ. However, since patients with metabolic syndrome ortype 2 diabetes are usually obese or overweight and have pathologicblood lipids, mainly elevated triglycerides and low High-DensityCholesterol (HDL-chol) activation of the PPARα receptor is important. Anideal drug for treatment of metabolic syndrome or type 2 diabetes shouldact as ligand to both these receptors, preferably with the highestaffinity to the PPARγ receptor.

Method

Ranking of the different DHA-derivatives according to their bindingaffinity was calculated and given as lowest binding affinity (LBA) andaverage binding affinity (ABE).

A total of 15 DHA derivatives (PRB-1 through PRB-15) were tested withthe computerized docking method. Some of the derivatives, such as PRB-1,PRB-2, PRB-7, PRB-9, PRB-10, PRB-11, PRB-12, PRB-13, PRB-14 and PRB-15,are presented as r and s enantiomeres and in this case both were tested.The PPARγ ligands rosiglitazone and pioglitazone, both in the r and sform, were also tested for comparison. These compounds are registeredpharmaceuticals for treatment of diabetes.

Results

The results are shown in Table 1, presenting the parameters Lowestbinding energy of single confirmation (LBE), average binding energy(ABE) of the correctly posed confirmation and fraction of correctlyposed confirmation of the ICM-saved 20 lowest energy confirmation(fbound) of the compounds tested. Affinity to the RXRα was tested in thesame setting. The RXRα receptor interacts with the PPAR receptor forminga heterodimer by liganding of a fatty acid.

FIG. 5 depicts the binding affinities for the PPARγ receptor, which ismainly engaged in the transcription of proteins engaged in handling ofblood glucose. Clearly PRB-2 both in the r and the s stereoisomer formshad a good affinity to the PPARγ receptor. PRB-5 scored somewhat poorerwhile PRB-8 had the highest ABE score. These findings are highlyunsuspected and could be translated into a more effective transcriptionof the respective PPARγ activated gene responsible for handling of bloodglucose.

FIG. 6 depicts the binding affinities to the nuclear receptor PPARαwhich is mainly responsible for metabolisation of fat, blood lipids, fattissue biology and weight control. Several DHA-derivatives had highbinding affinity but PRB8 had the highest score. This is also highlyunsuspected.

FIG. 7 depicts the binding affinities to the nuclear receptor RXRα. Thephysiologic consequence of binding to the RXRα receptor has not beenfirmly established. It is known that RXR binds to the PPAR receptorsthereby forming a heterodimer which then, subsequently, initiatestranscription of the defined gene.

TABLE 1 PPARα PPARγ RXRα LBE ABE ƒ_(bound) LBE ABE ƒ_(bound) LBE ABEƒ_(bound) DHA −16.14 −13.29 0.60 −11.34 −10.51 0.35 −12.15 −10.72 0.40(0.47) (0.21) (0.29) cr-PRB1 −16.29 −14.25 0.50 −12.96 −11.82 0.30−15.68 −14.25 0.30 (0.53) (0.38) (0.35) cs-PRB1 −15.97 −14.01 0.80−12.74 −10.24 0.65 −17.17 −14.48 0.50 (0.30) (0.48) (0.44) cr-PRB2−16.00 −14.02 0.50 −13.72 −12.17 0.25 −14.81 −12.80 0.20 (0.54) (0.54)(1.56) cr-PRB2 −16.86 −14.48 0.85 −13.34 −12.05 0.60 −15.57 −12.39 0.20(0.27) (0.30) (2.20) PRB5 −16.54 −14.37 0.65 −13.16 −11.88 0.50 −18.21−15.028 0.30 (0.40) (0.30) 1.03) cr-PRB7 −17.06 −15.09 0.80 −12.52 −8.340.50 −16.35 −13.72 0.30 (0.32) (2.30) (0.96) cs-PRB7 −16.31 −14.72 0.65−14.00 −10.84 0.55 −14.63 −12.52 0.30 (0.37) (0.40 (0.84) PRB8 −18.45−16.41 0.45 −13.39 −13.04 0.10 −17.31 −15.79 0.30 (0.57) (0.35) (0.57)sROSI −9.47 −9.01 (0.17) 0.20 sROSI −10.05 −7.89 (0.91) 0.20 rPIO NDsPIO −7.59 −7.59 0.05 cr-PRB9 −17.15 −15.12 0.35 −15.14 −12.84 0.25−17.56 −14.30 0.15 cs-PRB9 −15.66 −14.06 0.45 −13.50 −13.50 0.05 −16.63−15.20 0.15 cr-PRB10 −14.88 −13.46 0.25 −7.31 −7.31 0.05 −15.59 −15.580.10 cs-PRB10 −15.17 −12.90 0.50 −11.78 −9.64 0.20 −14.75 −13.05 0.30cr-PRB11 −16.50 −12.76 0.30 ND ND ND −15.26 −13.56 0.10 cs-PRB11 −17.77−13.66 0.20 ND ND ND −14.48 −13.48 0.20 cr-PRB12 −13.23 −11.61 0.65−11.11 −8.61 0.30 −14.73 −13.13 0.35 cs-PRB12 −15.10 −10.60 0.55 −9.64−8.20 0.45 −14.08 −8.67 0.60 cr-PRB13 ND ND — ND ND ND −13.20 −10.950.25 cs-PRB13  −6.89 −6.89 0.05 ND ND ND −11.84 −13.10 0.50 cr-PRB14−14.96 −11.99 0.60 −9.50 −8.72 0.20 −15.84 −14.77 0.20 cs-PRB14 −15.42−11.89 0.40 −11.29 −10.87 0.20 −15.22 −12.77 0.30 cr-PRB15 −14.62 −11.880.45 −12.49 −11.05 0.45 −17.01 −13.73 0.45 cs-PRB15 −15.90 −12.90 0.40−12.15 −10.55 0.50 −16.93 −13.27 0.60 ND = Not docked, c = the doublebonds in all-cis form. r = R enantioisomer, s = S enantioisomer. ROSI =Rosiglitazone, PIO = Pioglitazone

Several of the PRBs have a high LBE and ABE score for the PPARα andPPARγ receptors even compared to the mother compound DHA but also to thePPARγ ligands rosiglitazone and pioglitazone, both in the r and s form.This is an interesting observation indicating that several of the PRBscould be promising competitors to the established anti-diabeticsrosiglitazone and pioglitazone.

Ethyl derivativates in alfa position of the same fatty acids, both the rand the s form, did not improve affinity. This was especially true forthe PPARγ receptor. As mentioned previously the PPARα receptor is morepromiscuous binding a long series of fatty acids.

In conclusion, many of the DHA-derivatives tested demonstratedinteresting affinities to the PPARα and PPARγ receptors with bindingaffinities better than rosiglitazone and pioglitazone.

Example 3 Affinity Testing in Transfected Cells (Block 3 in FIG. 2)

Background

Release of luciferase is correlated to transcription of genes. Bindingof a ligand to a nuclear receptor such as PPARγ induces transcription ofthe respective gene thereby releasing luciferase. This techniquetherefore provides a measure of ligand affinity to the receptor as wellas activation of the responsible gene.

Method

Transient transfection of COS-1 cells was performed in 6-well plates asdescribed by Graham and van der Eb (Graham). For full length PPARtransfection studies, each well received 5 μg reporter construct, 2.5 μgpSV-β-galactosidase as an internal control, 0.4 μg pSG5-PPARγ2. Thecells were harvested after 72 h, and the luciferase activity wasmeasured according to the protocol (Promega). The luciferase activitywas normalised against β-galactosidase activity. The adipocytes weretransfected at D11 of differentiation using 16 μl LipofectaminPlusreagent, 4 μl Lipofectamine (Life Technologies Inc.), 0.2 μg pSG5-PPARγ,and 100 ng pTK Renilla luciferase as control of transfection afficiency.Three hours after transfection, cells were cultured in serum containingmedium and incubated for 48 hours in the same medium containingappropriate agents. The luciferase activities were measured asrecommended by the manufacturer (Dual Luciferase assay, Promega). Alltransfections were performed in triplicate.

Fatty acids (BRL or DHA) and PRBs (stock solutions) were solubilized to0.1 M final concentration in DMSO. Then, Fatty solubilized to 10 mM inDMSO and stored in 1.5 ml tubes (homoplymer, plastic tubes) flushed withargon and stored at −20° C. 10 μM of PRBs or fatty acids and DMSO(control) was added to the media 5 h after transfection. Transfectedcells were maintained for 24 h before lysis by reporter lysis buffer.Binding of PRBs or fatty acids to the LBD of PPAR activates GAL4 bindingto UAS, which in turn stimulates the tk promoter to drive luciferaseexpression. Luciferase activity was measured using a luminometer(TD-20/20 luminometer; Turner Designs, Sunnycvale, Calif.) andnormalized against protein content.

Results

FIG. 8 depicts the release of luciferase from transfected cells treatedwith different PRBs. The results indicate that PRB-1,2,6,7 and 14 have asignificantly higher release of luciferase compared toPRB-3,5,9,10,11,12, and 16.

Example 4 Affinity Testing in Adipose Prone Animals with MetabolicSyndrome (Block 4 in FIG. 2)

Background

An animal model of the metabolic syndrome using the adipose prone miceof the C57BL/6J strain was used to test affinity of PRB-2,5, and 8compared to 97% DHA and the antidiabetic compound rosiglitazone toPPARγ, by measuring the release of luciferase from adipose celles takenfrom these animals. The animals (n=8 in each group) were fed high fatdiet (fat constituting 60% of total calories, the same diet as used inBlock 5) for 8 weeks. Thereafter they were given the PRBs in a dose of1.5% of the fat content of the diet for another two weeks. Therosiglitazone group was given an amount of 100 mg/KG diet. The controlgroups continued with either only high fat diet or standard chow. FIG. 9shows the study design.

Method

After sacrifice adipose tissue (epididymal and subcutaneous) was clearedfrom other structures and cut into millimeter-size pieces. Fat tissuewas rinsed in 0.9% NaCl and digested in 5 mL of Krebs-Ringer solutioncontaining Hepes, fatty-acid free bovine serum albumin, 200 nM ofadenosin, 2 nM of glucose, and 260 U/mL of collagenase for 1.5 h at 37degrees C. in a shaking water bath. After collagensae digestion,adipocytes were separated from tissue debris by filtering. Cells werethen washed in Krebs-Ringer solution containing Hepes, fatty-acid freebovine serum albumin, 200 nM of adenosin, 2 nM of glucose and kept in ashaking water bath at 37 degrees for a maximum of 30 min untilelectroporation.

Isolated primary adipocytes were transfected by electroporation tomeasure the specific PPAR gamma response element (PPRE) activity. Inthis case we incorporated a plasmid encoding firefly luciferase cDNAunder control of a PPRE from the acyl-CoA-oxidase gene. The cells werealso co-transfected with a plasmid containing cDNA for Renillaluciferase controlled by a constitutively active promoter. The PPREinducible firefly luciferase activity was normalised according toRenilla luciferase, thus correcting for potential differences in theamount of transfected cells. To measure luciferase signal we used theDual-Luciferase® Reporter assay System (Promega, USA).

Pooled epidydimal fat tissue was enough to isolate adipocytes forrunning duplicates. Each of groups was sacrificed in two separated days,and 4 independent transfections for each dietetic group were obtained.

Results

During first 8 weeks of feeding with HF diet (33.7% of fat, w/w), therewas a gradual increase of body weight in comparison to control mice fedwith chow diet (4.5% w/w). During last 2 weeks of feeding withexperimental diets high fat diet animals and animals given high fat dietin combination with Rosiglitazon continued gaining weight, approximatelywith the same rate as before. In case of PRB-8 and PRB-5 enriched HFdiet the weight gain was reduced. However, in case of PRB-2 and DHA (5%w/w) the diet completely stopped the weight gain and even led toreduction of body weight (FIG. 10). Food consumption was recordedoccasionally (4×). There were no differences between the HF and theintervention groups.

In case of high fat in combination with Rosiglitazon, the endogenousactivity of PPARγ was approximately 2-fold higher than in all the othersdiet groups (FIG. 11). Furthermore, these fat cells became moresensitive to additional in vitro stimulation with 5 uM Rosiglitazon (5,12-fold stimulation) in comparison to i.e. HF diet itself (1,5-foldstimulation). This rosiglitazon—sensitizing effect was also recorded inthe PRB-2 and the PRB-5 diet group (2,6-fold stimulation).

Data from this study clearly demonstrates acitivity on the nuclear PPARreceptors, in particular with the effects on weight which was mostprominent for the groups given PRB-2. Even animals given PRB-5 and PRB-8did not increase in weight as did the high fat diet group. Interestinglyanimals given rosiglitazone increaed in weight to the same extent asanimals given only the high fat diet. This clearly demonstrates thenegative effects of giving only a PPARγ ligand, like the glitazones,with the risk of weight increase even if insulin resistance is reduced.However, when it comes to PPARγ activation measured as luciferaseactivity in this experiment, rosiglitazone scores higher compared to anyof the PRBs. Within the PRB groups PRB-2 and PRB-5 had a higher scorecompared to PRB-8 and DHA only (FIG. 12).

Example 5 Pharmacodynamic Effects of DHA Derivatives in an Animal Modelof Metabolic Syndrome (Block 5 in FIG. 2)

Background

An animal model of the metabolic syndrome using the adipose prone miceof the C57BL/6J strain was used to document effects on typicallaboratory and pathological anatomical features common for the metabolicsyndrome. When given a high fat diet containing about 60% of fat, theanimals are getting obese developing high insulin plasma levels,pathological glucose tolerance test, elevated serum triglycerides andnon-esterified fatty acids, and fat liver.

Example 5a Effect of DHA Derivatives in Adipose Prone Mice During 4Months of Dietary Interventions

Method

All experiments were performed on male C57BL/6 mice, either a substrainC57BL/N (supplier: Charles River, Germany, n=160, experiments A-C, seebelow), or a substrain C57BL/6J (supplier: the Jackson laboratory, BarHarbor, Me., USA, n=32, experiment D). Total numbers of animals usedwere higher (n=170 and 36, respectively), because of culling. In thelatter case, animals were bred for several generations (<20) at theInstitute of Physiology. At the beginning of the treatment, animals were14-week-old and their body weight range was 23.6-27.1 g. One week beforethe study start, animals were sorted according to their body weight andassigned to subgroups (n=8) of similar mean body weight. This methodallowed for culling of about 5-10% of animals showing the lowest andhighest body weight, respectively. The animals eliminated from the studyat this stage were sacrificed by cervical dislocation. Complete healthcheck of mice was performed by the supplier Charles River and at thestart of study serological tests were performed by ANLAB (Prague, CzechRepublic). In addition, regular health checks were performed in theanimal house in 3-mo-intervals using sentinel mice and serologicalexaminations (ANLAB). In all the tests, the animals were free ofspecific pathogens.

Diets

Animals weree fed 3 types of experimental diets:

-   -   (i) Chow diet (ssniff R/M-H from SSNIFF Spezialdieten Gmbh,        Soest, Germany; see also http://ssniff.de) with protein, fat and        carbohydrate forming 33, 9, and 58 energy %, respectively    -   (ii) High-fat diet prepared in the laboratory (cHF diet) with        protein, fat and carbohydrate forming 15, 59, and 26 energy %,        respectively, and well characterized fatty acid composition        (with most of the lipids coming from corn oil; see Ruzickova        2004)    -   (iii) cHF diets in which 0.15, 0.5, and 1.5% of fat        (specifically the corn oil constituent) was replaced by various        PRB-compounds, namely PRB1, PRB2, PRB5, PRB7, and PRB8, or by        DHA. All these compounds were in the form of ethyl esters,        provided by Pronova Biocare a.s. in sealed containers. Chemical        composition of the PRB-compounds was unknown to the laboratory        performing the experiments (Institute of Physiology, Academy of        Sciences Prague, Czech Republic).

After arrival, the PRB-compounds were stored in a refrigerator inoriginal containers. The containers were opened just before preparationof the experimental diets. Diets were kept in plastic bags flushed bynitrogen and stored at −70° C. in small aliquots sufficient for feedinganimals for one week. Fresh ratios were given in 2-day intervals ordaily.

Outline of the Study

The study was based on 4 individual experiments. In each of theexperiments, different PRB-compounds (or DHA, respectively) admixed tocHF diet in three different concentrations (0.15, 0.5, and 1.5% of thefat content) were tested. In each experiment, a subgroup of plain cHFdiet-fed mice was included and served as a control. Mice were caged ingroups of 4 and fed standard chow diet until 3 mo of age, when animals(n=8-13) were randomly assigned to the different test diets. After 2 moon this new diet (at 5 mo of age), animals were fasted overnight and inthe morning, intraperitoneal Glucose Tolerance Test (GTT) was performed.Animals were sacrificed after 4 months on the experimental diets, at 7mo of age, and the end-point analysis were performed.

Study Parameters.

The parameters in the study were: Body weight gain (grams), area underthe curve (AUC) from intraperitoneal glucose tolerance tests (mMol×180min), plasma insulin (ng/ml), serum triglycerides (TAGs, mmol/l), andnon-esterified fatty acids (NEFA, mmol/l).

FIG. 13 shows a typical blood glucose elimination curve before and afteranimals with insulin resistance are given a compound with insulinresistance reducing effect. Reduction of the area under the curve meansthat blood glucose is eliminated more effectively due to reduced insulinresistance.

Results

The results are shown in the following tables 2, 3 and 4. (*=significantdifferencies compared to cHF diets (P<0.05).)

Table 2 shows the effects in animals given 1.5% concentration of the PRBtest compounds compared to animals given standard chow (STD), compositehigh fat diet (cHF) or 97% DHA. Body weight gain was significantlyreduced in animals given PRB-2 compared to animals given high fat diet(cHF). Food intake was somewhat lower in this group. The most pronouncedreduction in AUC from glucose tolerance tests was seen in the same groupand even in animals given PRB-1. Plasma insulin was significantly lowerin the PRB-2 group compared to the cHF controls even if the PRB-1 andPRB-5 treated animals showed some effect on this parameter too. ThePRB-2 group showed the biggest reduction in triglycerides (TAGs) andnon-esterified fatty acids (NEFA).

Table 3 shows the effects in animals given a lower concentration, 0.5%,of the PRB test compounds compared to animals given standard chow (STD),composite high fat diet (cHF) or 97% DHA. Body weight gain was somewhatlower in animals given PRB-2 and PRB-5. AUC from the glucose tolerancetest as well as plasma insulin, however, was significantly lower only inthe PRB-2 group.

Table 4 shows the rsults from the lowest PRB concentration given, 0.15%.Here, the differences were small. Weight gain was somewhat lower in thePRB-1 and PRB-2 groups while AUC was significantly lower only in thePRB-2 group. Plasma insulin was lower in PRB-1,2 and 7.

TABLE 2 The effect of PRB derivatives after 4 months of treatment with1.5% concentration Parameter STD cHF PRB-1 PRB-2 PRB-5 PRB-7 DHA Bodyweight 32.4 ± 0.7  49.6 ± 0.6  44.0 ± 1.5* 30.1 ± 1.1*  46.3 ± 1.6 45.9± 1.1* 47.1 ± 0.7* (grams) Body wt. gain 7.8 ± 0.4 25.2 ± 0.5  20.2 ±1.3* 6.4 ± 0.8* 22.4 ± 1.4 21.7 ± 0.9* 23.0 ± 0.8* (grams) Food intake3.64 ± 0.04 2.70 ± 0.02 2.64 ± 0.03 2.38 ± 0.05*  2.62 ± 0.02 2.68 ±0.03 2.63 ± 0.02 (grams/mouse/day) AUCglucose 1124 ± 57  1625 ± 151  913± 68* 982 ± 80*  1264 ± 192 1122 ± 73  2132 ± 288* (mM × 180 min) Fastedglucose 77 ± 3  145 ± 7  130 ± 14  95 ± 6*  136 ± 12 120 ± 9  138 ± 7 (mg/dL) Insulin 1.03 ± 0.09 5.35 ± 0.36 2.73 ± 0.33 0.60 ± 0.18*  2.47 ±0.19* 4.42 ± 0.87 6.55 ± 0.31 (ng/mL) TAGs 1.41 ± 0.09 1.45 ± 0.07 1.58± 0.08 0.71 ± 0.01*  1.19 ± 0.07 1.15 ± 0.08  1.91 ± 0.26* (mmol/L) NEFA0.57 ± 0.05 0.61 ± 0.04  0.63 ± 0.03* 0.54 ± 0.03*  0.72 ± 0.05 0.82 ±0.06 0.98 ± 0.07 (mmol/L)

TABLE 3 The effect of PRB derivatives after 4 months of dietaryinterventions: 0.5% concentration. Parameter STD CHF PRB-1 PRB-2 PRB-5PRB-7 DHA Body weight 32.4 ± 0.7  49.6 ± 0.6  47.4 ± 0.6  45.8 ± 1.7 45.7 ± 1.5  48.8 ± 0.9  46.9 ± 0.7* (grams) Body wt. gain 7.8 ± 0.4 25.2± 0.5  23.8 ± 0.5  21.9 ± 0.6  22.0 ± 1.4  24.8 ± 0.8  22.9 ± 0.7*(grams) Food intake 3.64 ± 0.04 2.70 ± 0.02 2.67 ± 0.04 2.69 ± 0.04 2.63± 0.02 2.69 ± 0.03 2.70 ± 0.03 (grams/mouse/day) AUCglucose 1124 ± 57 1625 ± 151  1596 ± 205  1224 ± 72*  1581 ± 231  1674 ± 203  1816 ± 182 (mM × 180 min) Fasted glucose 77 ± 3  145 ± 7  131 ± 7  136 ± 7  130 ±7  152 ± 6  136 ± 8  (mg/dL) Insulin 1.03 ± 0.08 5.35 ± 0.36 3.93 ± 0.59 2.75 ± 0.21* 5.12 ± 0.93  4.10 ± 0.57* 5.82 ± 0.47 (ng/mL) TAGs 1.41 ±0.09 1.45 ± 0.07 2.03 ± 0.22 1.29 ± 0.08 1.46 ± 0.17 1.42 ± 0.08  1.78 ±0.08* (mmol/L) NEFA 0.57 ± 0.05 0.61 ± 0.04  0.73 ± 0.04* 0.75 ± 0.04 0.77 ± 0.03* 0.87 ± 0.04 0.89 ± 0.03 (mmol/L)

TABLE 4 The effect of PRB derivatives after 4 months of dietaryinterventions: 0.15% concentration. Parameter STD cHF PRB-1 PRB-2 PRB-5PRB-7 DHA Body weight 32.4 ± 0.7  49.6 ± 0.6  47.2 ± 1.3 46.7 ± 1.1 48.0 ± 0.8  47.4 ± 0.8* 48.3 ± 0.6 (grams) Body wt. Gain 7.8 ± 0.4 25.2± 0.5  22.9 ± 1.1 22.8 ± 0.9  24.2 ± 0.5  23.2 ± 0.7* 24.3 ± 0.8 (grams)Food intake 3.64 ± 0.04 2.70 ± 0.02  2.63 ± 0.04  2.57 ± 0.03* 2.66 ±0.02 2.59 ± 0.02  2.79 ± 0.03 (grams/mouse/day) AUCglucose 1124 ± 57 1625 ± 151  1291 ± 172 1071 ± 148* 1443 ± 70  1425 ± 97  1477 ± 214 (mM× 180 min) Fasted glucose 77 ± 3  145 ± 7  126 ± 15 132 ± 5  151 ± 5 141 ± 9  141 ± 10 (mg/dL) Insulin 1.03 ± 0.08 5.35 ± 0.36  3.50 ± 0.294.00 ± 0.64 6.21 ± 0.45  3.76 ± 0.72*  4.31 ± 0.39* (ng/mL) TAGs 1.41 ±0.09 1.45 ± 0.07  1.75 ± 0.08 1.42 ± 0.07 1.64 ± 0.28 1.41 ± 0.11  1.50± 0.13 (mmol/L) NEFA 0.57 ± 0.05 0.61 ± 0.04  0.62 ± 0.04* 0.78 ± 0.04*0.71 ± 0.09 0.85 ± 0.06  0.96 ± 0.07 (mmol/L)

In conclusion, testing of PBR-1,2,5, and 7 during 4 months in adiposeprone animals with insulin resistance and metabolic syndromedemonstrated a clear and unsuspected effect of the PRBs tested, inparticular the DHA-derivative PBR-2, on insulin resistance and symptomsof the metabolic syndrome such as weight reduction, reduced AUC in theintraperitoneal glucose tolerance test, lower insulin/plasma levels aswell as reduced triglyceride and non-esterified free fatty acids.Effects were observed in the dose of 1.5% as well as in the 0.5% group.Some effects were even noticed in the lowest concentration group of0.15%.

Testing of the PRB-8 compound was started later, therefore only datafrom 2 months intervention in three dose groups (1.5%, 0.5% and 0.15%)are given. In the group given 1.5%, body weight (BW) was 28.0±0.7 gramscompared to controls 29.6±0.9, AUC 1031±104 compared to 1074±91. Thesedifferences are small but the trend is interesting. There were nodifferences between intervention and controls for the lower doses of0.5% and 0.15%. The data regarding PRB-8 data from 2 months medicationshowing a trend towards weight reduction and AUC.

Example 5b

Effect of DHA Derivatives on Established Metabolic Syndrome and InsulinResistance

Method

In another experiment, PRB-2, PRB-5, and PRB-7 were tested in the samebreed of animals. In this experiment, animals were initially fed highfat diet (the same as in the previous experiment 5a) for 8 weeksdeveloping insulin resistance and the metabolic syndrome, and then giventhe PRBs. The start dose was to substitute 15% of the fat content withthe PRBs but the animals did not tolerate this dose. After a period ofanother two weeks the animals were given 1.5% of PRB-2, 5% and 1.5% ofPRB-5, and 1.5% and 0.5% of PRB-7.

Results

Weight reduction was very good in the animals given PRB-2. Even theanimals given PRB-5 showed some weight reduction but in the higher doseof 5%. Triglycerides were reduced with all derivatives tested comparedto the control animals fed composite High Fat diet. Reduction ofnon-esterified fatty acids was most pronounced with PRB-2 and PRB-5,however in different doses. (See FIG. 14)

Blood cholesterol was reduced in animals given PRB-2 and PRB-5. Bloodglucose was not affected due to the fact that these animals are in apre-diabetic state with normal glucose due to a high insulin production.However, more importantly, plasma insulin was significantly reduced inthe PRB-2 group in a much lower concentration compared to the secondbest DHA-derivative PRB-5. Even PRB-7 showed some effects on the insulinconcentration. (See FIG. 15)

PRB-2 showed a statistically significant reduction of the AUC bloodglucose at all time points of the curve compared to the baseline values.This means that blood glucose was more effectively removed aftertreatment of 1.5% of PRB-2. PBR-5 and PBR-7 showed some effect but notto the same extent. (See FIG. 16)

These effects are highly unsuspected and very relevant for a positiveeffect in metabolic syndrome and type 2 diabetes. These patients arealmost exclusively overweight or obese and a weight reductive effect ofa drug is highly positive. The mostly used remedies used for treatmentof type 2 diabetes today, the thiazolidinedions, which are potent PPARγligands thereby reducing insulin resistance, often result in weightincrease which is highly negative for these subset of patients(Yki-Järvinen 2004).

Reduction of serum triglycerides is another very important effect thatwas demonstrated in the experiments. Patients with metabolic syndromeand type 2 diabetes usually have elevated triglycerides. Thetriglyceride lowering effects of the DHA-derivatives is a positivefinding and again PRB-2 demonstrated the most potent effect with thelowest dose given. The very positive effects on plasma insulin andglucose tolerance test are very promising and highly unsuspected. Takentogether the effects obtained with the DHA-derivatives in particularPRB-2 are very promising forming a good basis for development of anantidiabetic drug.

Example 5c Testing of DHA Derivatives on Liver Fat

Method

Tissue samples from animals in the experiments with DHA derivatives washistologically analysed. After paraffination, tissue samples from liver,adipose tissue, skeletal muscle, pancreas, and kidney were stained witheosin-hematoxylin.

Results

There were no pathological findings in the tissues examined withexception from liver. Control animals fed high fat diet had developedfat liver (liver steatosis). Fat droplets in the liver can easily bedistinguished from normal liver cells. Animals treated with PRB-1, 5,and 7 had low degree of fat liver. However, animals treated with 1.5% ofPRB-2 had completely normal liver cells with no trace of steatosis.

This is an extremely important finding and very relevant for treatmentof patients with insulin resistance, obesity and type 2 diabetes. Liversteatosis is a common finding in these patients which is usually relatedto an overload of fatty acids and triglycerides, biological markerspresent in the development of insulin resistance and the metabolicsyndrome. DHA-derivatives reduce liver steatosis, and PRB-2 was the mostefficient compound showing this effect.

Discussion and Conclusions

The present application clearly identifies a new group of compoundswhich are activating nuclear receptors, especially PPARγ and PPARα,thereby offering a series of therapeutic effects in the treatment ofinsulin resistance, the metabolic syndrome, type 2 diabetes,cardiovascular disease and other atherosclerotic related diseases.

Members of this group are DHA derivatives with side chains of differentkind in the alfa position of the molecule. A large number ofalfa-substituted DHA derivatives have been tested and compared withcontrols as well as pure DHA and EPA. Several of the compounds testedhave demonstrated interesting biological effects very relevant for apotential anti-diabetic drug.

Interestingly, and not conceivable on beforehand, alfa-ethyl DHA ethylester (PRB-2) was significantly more effective in the battery of testsused to demonstrate effects related to insulin resistance and therebydiseases mainly caused by this pathophysiologic condition such as themetabolic syndrome, type 2 diabetes, cardiovascular disease and otheratherosclerotic related diseases. Alfa-ethyl DHA ethyl ester wasenriched in liver tissue from animals given the different DHAderivatives tested (Block 1) indicating that this compound was notutilised for synthesis of triglycerides, eikosanoids or other metabolicintermediates. Indirectly this would mean that alfa-ethyl DHA would beavailable for liganding to nuclear receptors like the PPARs.

In testing of affinity to PPAR γ and PPARα using computerized dockingtechnology a large number of the DHA-derivatives showed affinities toboth receptors, not least PPAR γ which probably is the most importantnuclear receptor engaged in the activation of genes responsible formetabolisation of blood glucose. In particular alfa-ethyl DHA (PRB-2) aswell as alfa-diethyl DHA (PBR-8) possessed excellent affinity to thesenuclear receptors. Compared to alfa-diethyl DHA alfa-ethyl DHA has twostereoisomers, the r and the s form. Using the docking technology bothstereoisomers possessed about the same affinity to PPAR γ and PPARαmeaning that neither the r or the s form should have advantages comparedto the racemic form. In fact the racemic form may have advantages overeach one of the stereoisomers.

When affinity was tested in transfected cells carrying the nuclearreceptor and the subsequent DNA response element, several of the PRBsdemonstrated good affinity measured as release of luciferase. Alfa-ethylDHA (PRB-2) together with PRB-6,7 and 14 demonstrated the best effects.

Five of the DHA derivatives have been extensively tested in the C57BL/6mouse model developing insulin resistance and the metabolic syndromewhen fed high fat diet. Alfa-ethyl DHA (PRB-2) has been tested in threeindividual experiments while PRB-1,5, and 7 were tested in two andalfa-diethyl DHA (PRB-8) was tested in one experiment. All derivativesdemonstrated significant biological effects. However, alfa-ethyl DHA(PRB-2) showed the most promising effects with a consistent reduction inbody weight, AUC from intraperitoneal glucose tolerance testing, plasmainsulin as well as serum triglycerides and non-esterified fatty acids.The effects were obtained on the doses 1.5% and 0.5%. The lowest testeddose 0.15% did not perform convincingly. Alfa-ethyl DHA (PRB-2) in adose of 1.5% has also demonstrated a normalisation of fat liver, animportant pathological finding in patients and animals with insulinresistance and metabolic syndrome.

Comparing with pure DHA, alfa-ethyl DHA (PRB-2) seems to be 10-30 timesas potent as DHA. All in all these findings and the potency compared tothe mother molecule DHA are not predictable and highly unexpected.

Since alfa-ethyl DHA (PRB-2) seems to work by simultaneous liganding tothe nuclear receptors PPARα and PPARγ the compound would not onlypossess therapeutic interesting effects on glucose and lipid metabolism,not least in patients with insulin resistance, metabolic syndrome andtype 2 diabetes but also have weight reduction as well as a generalanti-inflammatory effect. Directly or through positive intervention onrisk factors alfa-ethyl DHA (PRB-2) would have a preventive effect onthe development of cardiovascular disease such as myocardial infarctionand cerebral stroke as well as having a preventive effect oncardio-vascular mortality.

Pharmaceuticals acting as PPARγ ligands are already on the market buteven if these compounds are having positive effects on glucosemetabolism, they are hampered by adverse effects such as elevatedtriglycerides, weight increase and oedema. The alfa-substituted DHAderivatives presented in this application are having a combined PPARγand PPARα effect which is probably both relevant and advantageous forpatients with insulin resistance, metabolic syndrome and type 2diabetes. Furthermore, these combinative actions should have importanteffects also on blood lipids, inflammatory events, atherosclerosis, andthereby cardiovascular disease.

The invention shall not be limited to the shown embodiments andexamples.

REFERENCES

-   Simonopoulos A P. Essential fatty acids in health and chronic    disease. Am J Clin Nutr 1999;70 (Suppl):560S-569S-   Geleijnse J M, Giltay E J, Grobbee D E, et al. Blood pressure    response to fish oil supplementation: metaregression analysis of    randomized trials. J Hypertension 2002;20:1493-1499-   Storlien L H, Hulbert A J, and Else P L. Polyunsaturated fatty    acids, membrane function and metabolic diseases such as diabetes and    obesity. Curr Opin Clin Nutr Metab Care 1998;1:559-563-   Jump D B. The biochemistry of n-3 polyunsaturated fatty acids. J    Biol Chem 2002;277:8755-8758-   Pawar A and Jump D. Unsaturated fatty acid regulation of peroxisomes    proliferator-activated receptor alfa activity in rat primary    hepatocytes. J Biol Chem 2003;278:35931-35939-   Meigs J B, Wilson P W F, Nathan D M, et al. Prevalence and    characteristics of the metabolic syndrome in the San Antonio Heart    and Framingham offspring studies. Diabetes 2003;52:2160-2167-   Storlien L H, Kraegen W E, Chisholm D J, et al. Fish oil prevents    insulin resistance induced by high fat feeding in rats. Science    1987;237:885-888-   Field C J, Ryan E A, Thomson A B R, et al. Diet fat composition    alters membrane phospholipid composition, insulin binding and    glucose metabolism in adipocytes from control and diabetic animals.    J Biol Chemistry 1990;265:11143-11150-   Yki-Järvinen, H. Thiazolidinediones. NEJM 2004;351:1106-1118-   Adams M, Montague C T, Prins J B, et al. Activators of peroxisomes    proliferator-activated receptor gamma have depot-specific effects on    human preadipocyte differentiation. J Clin Invest 1997;100:3149-3153-   Ruzickovaj, Rossmeisl M, Prazak T, et al. Omega-3 PUFA of marine    origin limit diet-induced obesity in mice by reducing cellularity of    adipose tissue, Lipids 2004; 39:1177-1185-   Vaagenes H, Madsen L, Dyroy E, et al. The hypolipidaemic effect of    EPA is potentiated by 2- and 3-methylation. Biochim Pharmacol    1999;58:1133-1143-   Larsen L, Granslund L, Holmeide A K, et al. Sulfur-substituted and    α-methylated fatty acids as peroxisome proliferator-activated    receptor activators. Lipids 2005;40:49-57-   Larsen L, Hørvik K, Sørensen HIN, et al. Polyunsaturated thia- and    oxa-fatty acids: incorporation into cell-lipids and their effects on    arachidonic acid- and eikosanoids synthesis. Biochim et Biophys Acta    1997;1348:346-354-   Larsen, et. al Biochemical Pharmacology 1998; 55, 405-   Chih-Hao L, Olson P, and Evans R M. Lipid metabolism, metabolic    diseases, and peroxisome proliferator-activated receptors.    Endocrinology 2003;144:2201-2207-   Willumsen N, Waagenes H, Holmsen H, et al. On the effect of    2-deuterium- and 2-methyl-eicosapentaenoic acid derivatives on    triglycerides, peroxisomal beta-oxidation and platelet aggregation    in rats. Biochim Biophys Acta 1998;1369:193-203-   Mitsunobu O, Synthesis 1981;1-   Ager D J, Prakash I, and Schaad D R. 1,2-amino alcohols and their    heterocyclic derivatives as chiral auxiliaries in asymmetric    synthesis Chem Rev 1996;96:835-876

1. A compound of formula (I):

wherein R₁ and R₂ are the same or different and are chosen from ahydrogen atom, an alkyl group, a halogen atom, an alkoxy group, anacyloxy group, an acyl group, an alkenyl group, an alkynyl group, anaryl group, an alkylthio group, an alkoxycarbonyl group, analkylsulfinyl group, an alkylsulfonyl group, an amino group, and analkylamino group; and X represents a carboxylic acid group or acarboxylate group, or any pharmaceutically acceptable salt, solvate,complex or pro-drug thereof; with the provisos that: the compound offormula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA),alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethylester, or alpha-hydroxy DHA ethyl ester, and R₁ and R₂ are notsimultaneously a hydrogen atom.
 2. The compound according to claim 1,wherein the alkyl group is chosen from methyl, ethyl, n-propyl,isopropyl, n-butyl, iso-butyl, sec-butyl, and n-hexyl.
 3. The compoundaccording to claim 1, wherein the alkenyl group is chosen from allyl,2-butenyl, and 3-hexenyl.
 4. The compound according to claim 1, whereinthe alkynyl group is chosen from propargyl, 2-butynyl, and 3-hexynyl. 5.The compound according to claim 1, wherein the halogen atom is chosenfrom fluorine, chlorine, bromine, and iodine.
 6. The compound accordingto claim 1, wherein the alkoxy group is chosen from methoxy, ethoxy,propoxy, isopropoxy, sec-butoxy, phenoxy, benzyloxy, OCH₂CF₃, andOCH₂CH₂OCH₃.
 7. The compound according to claim 1, wherein the arylgroup is a phenyl group.
 8. The compound according to claim 1, whereinthe alkoxycarbonyl group is chosen from methoxycarbonyl, ethoxycarbonyl,propoxycarbonyl, and butoxycarbonyl.
 9. The compound according to claim1, wherein the alkylsulfinyl group is chosen from methanesulfinyl,ethanesulfinyl, and isopropanesulfinyl.
 10. The compound according toclaim 1, wherein the alkylsulfonyl group is chosen from methanesulfonyl,ethanesulfonyl, and isopropanesulfonyl.
 11. The compound according toclaim 1, wherein the alkylamino group is chosen from methylamino,dimethylamino, ethylamino, and diethylamino.
 12. The compound accordingto claim 1, wherein the carboxylate group is chosen from ethylcarboxylate, methyl carboxylate, n-propyl carboxylate, isopropylcarboxylate, n-butyl carboxylate, sec-butyl carboxylate, and n-hexylcarboxylate.
 13. The compound according to claim 1, wherein R₁ is ahydrogen atom, R₂ is an alkyl group, and X is a carboxylate group. 14.The compounds according to claim 13, wherein R₁ is a hydrogen atom, R₂is a n-propyl group, and X is an ethyl carboxylate group.
 15. Thecompound according to claim 1, wherein when R₁ and R₂ are not the same,the compound is present as the S enantiomer.
 16. The compound accordingto claim 1, wherein when R₁ and R₂ are not the same, the compound ispresent as the R enantiomer.
 17. The compound according to claim 1,wherein when R₁ and R₂ are not the same, the compound is present as theracemate.
 18. The compound according to claim 1, wherein when R₁ and R₂are not the same, the compound is present as a mixture of the R and Senantiomers.
 19. The compound according to claim 1, in the form of asalt wherein X is a COO⁻Z⁺, wherein Z⁺ is Li⁺, Na⁺, K⁺, NH₄ ⁺, orsubstituted NH₄ ⁺.
 20. The compound according to claim 1, in the form ofa salt according to the formula:

wherein Z²⁺ is Mg²⁺ or Ca²⁺.
 21. The compound according to claim 1,wherein X is a carboxylic acid derivative in the form of a triglycerideor a phospholipid.
 22. A compound of formula (I):

wherein R₁ and R₂ are the same or different and are chosen from ahydrogen atom, a hydroxy group, an alkyl group, a halogen atom, analkoxy group, and acyloxy group, an acyl group, an alkenyl group, analkynyl group, an aryl group, and alkylthio group, an alkoxycarbonylgroup, an alkylsulfinyl group, an alkylsulfonyl group, an amino group,or an alkylamino group; and X represents a carboxylic acid group, or anypharmaceutically acceptable salt, solvate, complex or pro-drug thereof;with the provisos that: the compound of formula (I) is not(all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA,alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester oraipha-hydroxy DHA ethyl ester, and R₁ and R₂ are not simultaneously ahydrogen atom.
 23. A compound of formula (I):

wherein R₁ and R₂ are the same or different and are chosen from ahydrogen atom, a hydroxy group, an alkyl group, a halogen atom, analkoxy group, and acyloxy group, an acyl group, an alkenyl group, analkynyl group, an aryl group, and alkylthio group, an alkoxycarbonylgroup, an alkylsulfinyl group, an alkylsulfonyl group, an amino group,or an alkylamino group; and X represents a carboxylic acid group,wherein the carboxylic acid is present as its diglyceride derivative;with the provisos that: the compound of formula (I) is not(all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA,alpha-methyl OHA methyl ester, alpha-methyl DHA ethyl ester oralpha-hydroxy DHA ethyl ester, and R₁ and R₂ are not simultaneously ahydrogen atom.
 24. The compound according to claim 23, wherein the alkylgroup is chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl,iso-butyl, sec-butyl, and n-hexyl.
 25. The compound according to claim23, wherein the alkenyl group is chosen from allyl, 2-butenyl, and3-hexenyl.
 26. The compound according to claim 23, wherein the alkynylgroup is chosen from propargyl, 2-butynyl, and 3-hexynyl.
 27. Thecompound according to claim 23, wherein the halogen atom is chosen fromfluorine, chlorine, bromine, and iodine.
 28. The compound according toclaim 23, wherein the alkoxy group is chosen from methoxy, ethoxy,propoxy, isopropoxy, sec-butoxy, phenoxy, benzyloxy, OCH₂CF₃, andOCH₂CH₂OCH₃.
 29. The compound according to claim 23, wherein the arylgroup is a phenyl group.
 30. The compound according to claim 23, whereinthe alkoxycarbonyl group is chosen from methoxycarbonyl, ethoxycarbonyl,propoxycarbonyl, and butoxycarbonyl.
 31. The compound according to claim23, wherein the alkylsulfinyl group is chosen from methanesulfinyl,ethanesulfinyl, and isopropanesulfinyl.
 32. The compound according toclaim 23, wherein the alkylsulfonyl group is chosen frommethanesulfonyl, ethanesulfonyl, and isopropanesulfonyl.
 33. Thecompound according to claim 23, wherein the alkylamino group is chosenfrom methylamino, dimethylamino, ethylamino, and diethylamino.